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Summary 
 
Decoy receptor 3 (DcR3) is a member of the tumor necrosis factor (TNF) 
receptor family, and is widely expressed in human normal tissues and 
malignant tumors. It is a decoy receptor of three TNF family members, i.e., 
FasL, LIGHT and TL1A. The interaction of DcR3 and its ligands will not 
transmit signal into cells via DcR3 because DcR3 is a soluble protein 
without a transmembrane and intracellular segment. Thereby, DcR3 
competitively inhibits signaling through three functional receptors, i.e., Fas, 
HVEM/LTβR and DR3. 
In previous studies, we found that DcR3 could modulate immune cell 
function, and protect islet viability. Herein, we generated DcR3 transgenic 
(Tg) mice driven by the human β-actin promoter to further investigate the 
function of DcR3. 
Interestingly, the DcR3 Tg mice developed a lupus-like syndrome at 6 
months of age. They presented a variety of autoantibodies including anti-
nucleus and anti-dsDNA antibodies. They also manifested renal, dermal, 
hepatic and hematopoietic lesions. Compared to lpr and gld mouse lupus 
models, DcR3 Tg mice more closely resembled human SLE in terms of 
Th2-biased immune response and anti-Sm antibody production. 
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Furthermore, we found that DcR3-producing hematopoietic cell were 
sufficient to cause these pathological changes. Mechanistically, DcR3 may 
break T-cell homeostasis to interfere with peripheral tolerance, and then 
induce autoimmunity.    
In humans, we detected high DcR3 levels in SLE patient sera. The high 
DcR3 levels were related to elevated IgE titer in some SLE patients, as was 
the case in the mouse model. Therefore, DcR3 may represent an important 
pathogenetic factor of human SLE.  
Utilizing the DcR3 Tg mouse, we further elucidated the mechanism by 
which DcR3 protected islets from primary nonfunction (PNF). Blocking of 
LIGHT and TL1A signaling by DcR3 are involved in such protection. 
Moreover, by mRNA microarray we identified possible downstream 
molecules, which may mediate such protection. We confirmed that 
Adcyap1 and Bank1 played critical roles in mediating DcR3’s effect in 
islet protection.  
Our studies resolved a puzzle about the relationship between the Fas/FasL 
apoptosis signaling pathway and the pathogenesis of human SLE. DcR3 
can block Fas/FasL pathway even if there is no genetic mutation in Fas and 
FasL. DcR3 can simultaneously interfere with LIGHT and TL1A signaling 
to cause a more complex phenotype than the simple Fas or FasL mutation 
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in patients. DcR3 can also be employed as a potential diagnostic parameter 
for SLE. The discovery of the mechanism of DcR3 in protecting islets 
allows us to explore novel therapeutic targets to protect islet graft.  
  
 
 
 
 
Key words:  DcR3; transgenic; systemic lupus erythematosus; islet transplantation; 
primary nonfunction ( PNF). 
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Résumé 
 
Le récepteur DcR3 (Decoy receptor 3) est un membre de la famille des 
récepteurs aux facteurs de nécrose tumorale (TNF). Il est fortement 
exprimé dans les tissus humains normaux ainsi que les tumeurs malignes. 
DcR3 est un récepteur pour trois ligands de la famille du TNF tels que  
FasL,  LIGHT et TL1A. Étant une protéine soluble donc dépourvue de la 
portion transmembranaire et intracytoplasmique, le récepteur DcR3 est 
incapable d’effectuer une transduction de signal intracellulaire à la suite de 
son interaction avec ses ligands. De ce fait, DcR3 joue un rôle de 
compétiteur pour ces derniers, afin d’inhiber la signalisation via leurs 
récepteurs fonctionnels tels que Fas,  HVEM/LTβR et DR3. 
Lors de nos précédentes études, nous avons pu démontrer, que DcR3 
pouvaist moduler la fonction des cellules immunitaires, et aussi protéger la 
viabilité des îlots de Langerhans. À la suite de ces résultats, nous avons 
généré des souris DcR3 transgéniques (Tg) en utilisant le promoteur du 
gène β-actine humaine afin d’étudier plus amplement la fonction de ce 
récepteur.  
Les souris Tg DcR3 ont finalement développé le syndrome lupus-like 
(SLE) seulement après l’âge de 6 mois. Ces souris présentent une variété 
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d'auto-anticorps comprenant des anticorps anti-noyaux et anti-ADN. Elles 
ont également manifesté des lésions rénales, cutanées, hépatiques et 
hématopoïétiques.  Contrairement aux modèles de lupus murin lpr et gld,  
les souris DcR3 sont plus proche du SLE humain en terme de réponse 
immunitaire de type Th2 et de production d'anticorps d'anti-Sm. En péus, 
nous avons constaté que les cellules hématopoïétiques produisant DcR3  
sont suffisantes pour causer ces pathologies. DcR3 peut agir en perturbant 
l’homéostasie des cellules T pour interférer avec la tolérance périphérique, 
et ainsi induire  l'autoimmunité.  
Chez l'humain, nous avons détecté dans le sérum de patients SLE des 
niveaux élevés de la protéine DcR3. Chez certains patients, comme chez la 
souris, ces niveaux sont liés directement aux titres élevés d’IgE. Par 
conséquent, DcR3 peut représenter un facteur pathogénique important du 
SLE humain.  
 L’étude des souris Tg DcR3, nous a permis aussi d’élucider le mécanisme 
de protection des îlots de Langerhans. Le blocage de la signalisation des 
ligands LIGHT et TL1A par DcR3 est impliqué dans une telle protection. 
D'ailleurs, nous avons identifié par ARN microarray quelques molécules 
en aval de cette interaction, qui peuvent jouer un rôle dans le mécanisme 
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d’action. Nous avons par la suite confirmé que Adcyap1 et Bank1 joue un 
rôle critique dans la protection des îlots de Langerhans médiée par DcR3. 
 Notre étude a ainsi élucidé le lien qui existe entre la signalisation 
apoptotique médiée par Fas/FasL et la pathogénèse du SLE humain. Donc, 
malgré l’absence de mutations génétiques sur Fas et FasL dans le cas de 
cette pathologie, DcR3 est capable de beoquer cette signalisation et 
provoquer le SLE chez l’humain. Ainsi, DcR3 peut simultanément 
interférer avec la signalisation des ligands LIGHT et TL1A et causer un 
phénotype plus  complexe que les phénotypes résultant de la mutation de 
Fas ou de FasL chez certains patients. DcR3 peut également être utilisé 
comme paramètre  diagnostique potentiel pour le SLE. Les découvertes du 
mécanisme de  protection des îlots de Langerhans par DcR3 ouvrent la 
porte vers de nouveaux horizons afin d'explorer de nouvelles cibles 
thérapeutiques pour protéger la greffe d'îlots.  
 
 
 
 
 
Mots clés : DcR3; transgénique; systemic lupus erythematosus; transplantation d'îlots; 
PNF. 
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 1.  Decoy receptor 3 
 
1-1. General information about DcR3 
Decoy receptor 3 (DcR3) is a member of the tumor necrosis factor receptor 
(TNFR) family. Its full-length complementary DNA was first isolated from 
human fetal lung in 1998 by Pitti et al (1). The DcR3 gene is mapped to 
chromosome 20q13.3, a region associated with gene amplification and 
rearrangement in human cancer (2,3). The DcR3 cDNA encodes a 300-aa 
secreted protein that lacks transmembrane and intracellular domains in its 
sequence (1,4). It contains 4 conserved cysteine-rich domains (CRD) as 
other members of TNFR family, and one N-linked glycosylation site 
(Fig.1). There are two transcription variants of DcR3 at the 5' untranslated 
region but they encode the same protein (NM_032945.2 and 
NM_003823.2). DcR3 is expressed in humans, chicken (5), and Conger 
myriaster (6). The rodents do not have any homologue of DcR3 according 
to genome-wide computer search. 
DcR3 is present in the normal human fetal lung, brain, and liver, also in the 
adult spleen, colon, lung, and activated T cells (1,7). More interestingly, it 
is highly expressed in many malignant tumors/cells. Overexpression of 
DcR3 has been reported in 34% (27/79) gastric carcinoma (8), in 44% 
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(30/68) gastrointestinal tract adenocarcinomas (9), in 63%-73% (185/294- 
163/223) colorectal tumors (10), in 60% (29/48) hepatocellular carcinoma 
(11), in 67% (10/15) pancreatic cancer (12), and in 83% (15/18) of 
high-grade gliomas (13). It is also found in lymphomas, renal cancers and 
ovarian cancers (14,15,16). According to our ELISA analysis, about 
50–60% of various tumors overexpressed DcR3 (17). 
 
Figure 1. The homology of the amino-acid sequences between DcR3 and OPG (osteoprotegerin, a 
typical member of TNFR family) (source: ref.1) 
Arrow: the putative signal cleavage site; 
CRD: the cysteine-rich domains; 
Asterisk: the N-linked glycosylation site.  
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1-2. Biological function of DcR3 and its molecular mechanism  
Although the DcR3 does not transmit signal into cells, it is able to bind 
three TNF family members, i.e., FasL (Fas ligand), LIGHT 
(lymphotoxin-like, exhibits inducible expression, and competes with HSV 
glycoprotein D for HVEM) and TL1A (TNF-like molecule 1A) (1,4,9,18). 
Such competition will disturb the interaction of these molecules with their 
functional receptors, i.e., FasL with Fas, LIGHT with HVEM (herpesvirus 
entry mediator protein) (19,20) and LTβR (lymphotoxin  receptor) 
(21,22), and TL1A with DR3 (death domain-containing receptor 3) (18). 
As a consequence, DcR3 competitively suppresses signaling through these 
receptors, and interferes with their functions. A brief review of the 
functions of Fas, LIGHT and TL1A is given below. 
1-2-1. Fas and FasL: Fas antigen, also known as CD95 or APO-1, is a 
principal death receptor to trigger apoptosis signaling pathway (Fig.2). 
Various types of cells express Fas, including most immune cells (i.e., T 
cells, activated B cells, mononuclear phagocytes) and some non-immune 
cells in the liver, lung, heart (23) and islets of Langerhans (24). Fas 
contains a conserved “death domain” in its cytoplasmic region. FasL is a 
homotrimeric membrane protein which is predominantly expressed on 
activated T cells. When FasL binds to Fas, it clusters 3 or more Fas 
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molecules to form the death-induced signaling complex (DISC). The 
death domain of the Fas polymer recruits Fas-associated death domain 
(FADD). The death effector domain of FADD consequently binds to 
FADD-like ICE (FLICE), or more commonly known as pro-caspase 8. 
FLICE can be cleaved into p10 and p18 subunits through self-proteolysis, 
and form an active heterotetramer enzyme. Active caspase-8 is then 
released into the cytoplasm to cleave and activate downstream effector 
caspases, such as caspases 3, 6, or 7. This eventually leads to DNA 
fragmentation, membrane blebbing, and cell death.  
 
Figure 2: The apoptotic signal pathway of Fas / FasL (CD95/CD95L). (source: ref. 25) 
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The Fas/FasL apoptosis signaling pathway is involved in T-cell 
homeostasis, the establishment of immune privilege, cytotoxic T-cell 
activity (26) and tumor cell survival (27). 
Besides triggering Fas positive cell to apoptosis, FasL may also act as a 
costimulator by retrograde signal transmission into FasL expressing cells 
by “reverse signaling” (28).  
 
1-2-2. LIGHT and HVEM/LTβR: LIGHT is a type-II transmembrane 
protein (29), and is highly expressed on activated lymphocytes, CD8+ T 
cell lines, granulocytes, and monocytes (22). LIGHT, as a costimulator 
through the LIGHT/HVEM interaction, contributes to T-cell activation 
and modulates T-cell responses (30,31,32). The LIGHT/HVEM signaling 
has been involved in graft-versus-host diseases (33,34). On the other 
hand, the LIGHT/LTβR signaling plays various biological activities, 
including the induction of apoptosis (35,36,37), organogenesis of lymph 
nodes (38), restoration of secondary lymphoid structure and function 
(39,40), and production of cytokines (41). Moreover, LIGHT produced 
by activated lymphocytes can induce apoptosis of tumor cells expressing 
both LTβR and HVEM (22). 
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1-2-3. TL1A and DR3: TL1A (TNFSF15/VEGI) is the most recently 
identified member of the TNF superfamily. It has been shown to be 
highly expressed on the membrane of endothelial cells, dendritic cells 
and peripheral CD4+CCR9+ T cells (18,42). It is also a soluble protein 
(often called vascular endothelial growth inhibitor [VEGI]), which is 
present in body fluids or secreted by TNF-α−treated chondrocytes 
(43,44). DR3 is a high affinity receptor for TL1A (18) and contains a 
death domain similar to Fas. DR3 is not only a transmembrane receptor 
on lymphocytes, but also function as a "decoy" receptor when secreted 
without the transmembrane domain. The signaling through DR3 can 
either induce apoptosis or activate NF-κB (45). In T cells, TL1A activates 
NF-κB and cIAP-2 as a costimulator through ligation with DR3, and 
leads to elevated secretion of IFN-  and GMCSF, but not apoptosis (46). 
This mechanism is involved in certain inflammatory diseases 
(inflammatory bowel disease, mucosal inflammation, and atherogenesis)  
(47,48,49). Furthermore, the TL1A/DR3 signaling regulates osteoblast 
differentiation and apoptosis, and may contribute to arthritis and bone 
cancer (50). 
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In addition to FasL, LIGHT and TL1A, there is some indication that DcR3 
might bind to other additional ligand(s) (51), but this has not been proven. 
Although mice do not express DcR3, studies by our team and Bossen et al. 
have showed that human that DcR3 can bind to mouse FasL, TL1A and 
LIGHT, and exert biological functions (4,52,53). DcR3 influences multiple 
physiological functions such as the induction of apoptosis (1,9,22,37,54), 
regulation of T-cell migration (55), regulation of angiogenesis (56), and 
modulation of macrophage and dendritic cell differentiation (57,58).  
 
1-3. Regulation of DcR3 expression 
The molecular mechanism regulating DcR3 expression in normal cells is 
not well elucidated. We know that DcR3 expression depends on the 
transcription factor NF-κB and the activation of mitogen-activated protein 
kinases (MAPK), such as extracellular signal-regulated kinase 1 and 2 
(ERK1/2) and c-Jun NH2-terminal protein kinase (JNK) (59). A very 
recent study showed that serum DcR3 levels have cyclic changes according 
to the menstrual cycle and DcR3 expression in endometrial cells is 
modulated by sex hormones (60). This study also suggested that the sex 
hormone-related signaling pathways may participate in the regulation.  
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In tumors, gene amplification and overexpression of DcR3 are frequently 
observed (1, 9). However, they are not always concurrent (9,61). Protein 
overexpression may not depend on genomic change, and the gene 
amplification may not cause the protein overexpression either. These 
suggest that the gene amplification is neither sufficient nor necessary for 
the overexpression of DcR3, and there are other mechanisms to modulate 
its expression level. Further studies found that insulin-like growth factor-1 
induced activation of the PI3K/Akt/NF- B signaling pathway is important 
to regulate endogenous DcR3 expression in human pancreatic carcinoma 
(62). Interestingly, DcR3 overexpression positively relates to Epstein-Barr 
virus (EBV) infection in lymphomas (63). Here, DcR3 expression is 
induced by Rta, a transcriptional activator encoded by EBV (64). Rta not 
only directly binds to the Rta-responsive element (RRE) sequence located 
in the DcR3 promoter region, but also enhances PI3-K activity. Besides, 
the coordinate transcriptional regulation of overlapped genes may be 
involved in the mechanism. The DcR3 gene is located in a gene-rich 
cluster and partially overlaps with exons 32 through 35 of the novel 
helicase-like gene (NHL) (Fig. 3), which relates to multiple inherited 
human neoplastic disorders (9).  Such overlapping structures could cause 
coordinate transcriptional regulation (65 ) that may contribute to the 
up-regulation of DcR3 in tumors or other diseases.  
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Figure 3. Genomic structure of DcR3 and adjacent genes. (source: ref. 9) 
Shaded boxes: Exons, each color represents one gene;  
Arrows: The translation initiation methionine and the direction of protein translation;  
*: One of DcR3 transcript variants overlaps the NHL helicase sequence with exons 32 through 35.  
 
1-4. Immunity and DcR3 
DcR3 plays a complex role in immune modulation. DcR3 primarily 
downregulates immune function. It could suppress T- and B-cell activation 
and T-cell proliferation (66), inhibit T-cell and macrophage chemotaxis 
(13,55,66), impair macrophage function (67), as well as induce apoptosis 
of dendritic cells (68). On the other hand, activated T cells secrete DcR3, 
which can prevent T cells from activation-induced cell death (AICD) (1) 
and enhance T-cell activation and cytokine production through 
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costimulation (69,70,71). It also regulates the differentiation of dendritic 
cells and macrophages (57, 58), and the expression of adhesion molecules 
on endothelial cells (72). The complexity of the bioactivity of DcR3 hints 
that DcR3 may participate in multiple physiological procedures and 
precisely adjust different signaling pathways according to certain 
circumstances.  
 
1-5. Cancer and DcR3 
As described, DcR3 overexpression is found in diverse malignant tumors. 
Clinical studies also show relationship between DcR3 levels and 
malignancy, tumor stage and prognosis. Higher serum DcR3 levels are 
associated with poorer differentiation, later tumor stages and worse 
outcomes (8,15,73 ,74). These observations and in vitro experiments 
(1,12,75) support the notion that tumors may benefit from the elevation of 
DcR3 levels to overcome immune surveillance. Indeed, DcR3 may provide 
several advantages to tumors: 
1) DcR3 may inhibit NK cell and cytotoxic T lymphocyte activity through 
blocking of the Fas/FasL, LIGHT/ HVEM-LTβR death signaling pathway; 
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2) DcR3 may suppress the tumor-reactive lymphocyte activation and 
cytokine production by repressing costimulation of LIGHT and TL1A, or 
by modulation of dendritic cells; 
3) DcR3 may restrain T lymphocyte chemotaxis by the activation of 
LIGHT reverse signaling; 
4) DcR3 may induce angiogenesis of tumors by neutralization of TL1A; 
5) DcR3 may disturb mononuclear phagocyte differentiation, adhesion and 
antigen presenting functions (57,72). 
Several questions remain to be answered. Which cells do contribute to 
increased serum DcR3 levels in tumor patients? Tumor cells, 
tumor-reactive immune cells, or both? Is DcR3 elevation a cause or a 
consequence of oncogenesis? In other words, could occasional elevated 
DcR3 levels induce malignant changes, or existing malignant cells and/or 
tumor-reactive immune cells over secrete DcR3? We do not have definitive 
answers to these questions. 
In our study, DcR3 transgenic mice do not produce any conspicuous 
tumors when expressing folds higher endogenous DcR3 than those 
observed from tumor patients (data not shown). This suggests that sole 
DcR3 overexpression may not be sufficient to induce but functions as an 
accessory factor to carcinogenesis. Up-regulated DcR3 levels, which are 
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caused by virus infection, endocrine disturbances, improper gene 
regulation, may assist the malignantly transformed cells to escape immune 
surveillance. In any case, DcR3 is becoming a useful early diagnostic and 
prognostic marker of various malignant tumors.  
In summary, DcR3 is a multifunctional regulator. It is not absolutely 
needed for normal physiological functions since rodents do not have it at 
all. Its biological function in humans might be fine tuning of certain 
signaling pathways. It may involve multiple organ development, immune 
system maturation, peripheral tolerance maintenance and tissue repair. 
Dysfunction of DcR3 may result in a variety of disorders in humans, and 
its expression could be used to monitor conditions of these diseases. 
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 2. Systemic lupus erythematosus (SLE) 
 
Systemic lupus erythematosus (SLE) is an autoimmune disease 
characterized by the production of many different autoantibodies against 
cell components, especially nuclear components, with involvement of 
multiple systems, and variable symptoms. Excessive autoantibodies lead to 
formation of immune complexes, with deposition in different tissues 
causing inflammation and consequent tissue damage. The clinical 
manifestations of SLE vary greatly. The course of the disease is 
characterized by alternative relapse and remission. 
 
2-1. Epidemiology of SLE 
Although about 20 percent of SLE patients are diagnosed before age 16 
(76)， SLE mainly affects child-bearing age females, and the disease lasts 
for life (77). It is more frequent among Asians, Afro-Americans and 
Afro-Caribbeans than Caucasians and Blacks in Africa (78,79,80). The 
prevalence of SLE is highly varied according to regions. In the USA, it is 
from 40 to 150 cases per 100,000 (81,82); in Asia, 50 to 100 cases per 
100,000 (83); about 20 to 70 per 100,000 in Europe (84,85,86). The 
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incidence has nearly tripled in the past 40 years, but this maybe due to 
improved detection of mild forms of the disease (87). 
 
2-2. Pathoaetiology of SLE 
Immune complex deposition, inflammation and vascular abnormalities are 
the basic pathological changes of SLE. Their central pathogenesis is the 
production of autoantibodies. Both T and B lymphocytes are necessary for 
the generation of autoantibodies. These antibodies aim several self 
molecules in the nucleus, cytoplasm, and cell surface, as well as some 
soluble molecules such as IgG and coagulation factors. Antinuclear 
antibodies are most common. The anti-double stranded DNA (ds-DNA) 
and anti-Sm antibodies are unique in SLE, and are thought to be the main 
reasons of tissue damage. When soluble self-antigens are exposed to 
autoantibodies, they form immune complexes, which are deposited in 
tissues, especially the joints, glomeruli and vascular wall. The deposited 
immune complexes will activate the complement system, which will then 
recruit and activate inflammatory cells, such as neutrophils and 
macrophages. These inflammatory cells will secrete reactive intermediates 
to mediate local inflammation. Subsequently, this leads to tissue damage 
and clinical symptoms. 
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In addition to T and B lymphocyte function which is important for 
autoantibody generation, other risk factors such as hormones, 
environmental elements and genetic susceptibility are also critical in SLE 
pathogenesis. 
 
2-2-1. Hormones  
Sex hormones are crucial in the pathogenesis of SLE. SLE is marked with 
female predominance. The female to male ratio of SLE patient rises from 
puberty (3: 1) and peak during child-bearing years (10-15: 1), it then 
decreases after menopause (8: 1) (88). High-estrogen levels, in the cases of 
early menarche, estrogen treatment, or Klinefelter’s syndrome that are 
characterized by hypergonadotrophic hypogonadism, could significantly 
increase the risk of SLE (89,90). Moreover, abnormalities of sex hormone 
metabolism including redundancy of 16 hydroxyestrone (91) and reduction 
of androgens (testosterone, dihydrotestosterone, dehydroepiandrosterone 
(DHEA) and dehydroepiandrosterone sulfate (DHEA-S) (92 ,93 )) are 
observed in both male and female SLE patients.  
Besides sex hormones, gonadotrophin releasing hormone (GnRH) (94) and 
hormones in the hypothalamo–pituitary–adrenal (HPA) axis (such as 
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cortisol, prolactin and thyrotropin releasing hormone) ( 95 , 96 ) also 
influence the invasion and/or activity of SLE. 
 
2-2-2. Genetic factors  
SLE shows a strong familial aggregation (10–12%) among first degree 
relatives (97). Moreover, the concordance of SLE in identical twins is 
significantly higher than that in dizygotic twins (25–50% vs. 5%) (98). 
These observations suggest that the genetic factors play an important role 
in the pathogenesis of SLE. Although few SLE cases (<5%) are caused by 
single gene mutations (99), SLE is primarily a polygenic inheritance 
disease, which needs at least four susceptible genes to cause disease 
manifestation ( 100 ). More than 100 potential risk genes have been 
identified in the last few decades. Some of them were confirmed to have 
strong association with SLE. Those include: the genes of human leukocyte 
antigen (HLA) class II [HLA-DRB1*0301/*0302 (DR3), 
DRB1*1501/*1503 (DR2), DRB1*08 (DR8) (101,102,103)], genes of 
some classical complement activation pathway components [C1q, C1r/s 
(104), C2 (105,106), C4 (107,108,109)], the FCGR genes [FcgR IIa (110), 
IIb (111) and IIIa (112)], and some genes related to immune regulation, 
e.g., TNF-α (113,114), PDCD1 (115,116) and CTLA-4 (117,118).  
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In addition to these candidate genes, 13 susceptibility loci show significant 
linkage to SLE, according to a genome-wide linkage analysis (Fig. 4) (119). 
Eight of them (1q23, 1q25-31, 1q41-42, 2q35-37, 4p16-15.2, 6p11-21, 12 
q24, and 16q12) were confirmed by a number of studies (120,121,122,123, 
124,125,126,127,128,129,130). 
 
 
Fig. 4 The susceptibility loci of SLE (source: ref.131) 
 
2-2-3. Environmental factors  
The genetic idiosyncrasy and hormonal surroundings create a 
predisposition to SLE, while environmental factors can trigger the 
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initiation of SLE. Ultraviolet (UV) light, especially UVB, can bring  
about keratinocytes apoptosis, and then expose some self-antigens to the 
immune system  triggering autoimmunity (132). Some chemicals, such as 
aromatic amines, hydrazines and their derivatives, are present in many 
drugs, agricultural and industrial products (even tobacco). They can 
potentially ignite a lupus-like syndrome ( 133 ). Infections in early 
childhood seem to affect the SLE risk in later life (134,135). Furthermore, 
the deficiency of vitamin D also has been found to be associated with SLE 
(136). 
 
2-2-4. Apoptosis and SLE 
Apoptosis, also called programmed cell death, is a process when cells 
undergo an ordered destruction and clearance, without releasing 
inflammatory intracellular contents into the extracellular environment. 
Apoptosis can be initiated by ligation of cell surface death receptors with 
their ligand(s), or by deficiency of survival stimuli. The former is called 
activation-induced cell death, and the latter is called passive cell death. In 
activation-induced cell death, ligated death receptor will activate caspase 8 
(and caspase 10 in humans). While lack of survival stimuli will increase 
permeability of mitochondria and lead to release of cytochrome C. 
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Cytochrome C then couple with apoptosis activating factor-1 to induce 
activation of caspase 9.  The activation of caspase 8 or caspase 9 is 
followed by the activation of an enzymatic cascade, nuclear condensation 
and fragmentation, and plasma membrane blebbing (137). Among all the 
cell death receptor/ligand signaling pathways, Fas/FasL-mediated 
apoptosis pathway is the best characterized (Fig 5). This pathway is crucial 
for the development of immune tolerance (138,139).  
During the immune system maturation, self-tolerance is developed through 
apoptosis of auto-reactive lymphocytes in central lymphoid organs. 
Immature T/B cells with high affinity receptor of self-antigen will be 
induced to apoptosis. This is called central tolerance. But not all of the 
self-antigen can be presented in central lymphoid organs. Some 
auto-reactive lymphocytes can escape from negative selection. In 
peripheral, apoptosis of activated lymphocytes following an immune 
response maintains homeostasis of peripheral lymphocytes numbers, and 
contributes to peripheral tolerance to self-antigens (140,141). Disturbance 
in these apoptotic processes might break the balance present in the immune 
system and may predispose to autoimmunity. Some lupus-prone murine 
models support this assumption. The lpr/lpr and gld/gld mice, which have 
mutation in the Fas and FasL respectively, spontaneously develop 
FACULTÉ  DES  ÉTUDES  SUPÉRIEURES  UNIVERSITÉ  DE  MONTRÉAL      BING HAN 21
lymphadenopathy and lupus-like syndrome characterized by the presence 
of autoantibodies to nuclear antigens ( 142 ). Another model is the 
exogenous soluble Fas (sFas)-induced autoimmune symptoms in CD1 
mouse (143). These models suggest that the disorder or blocking of 
Fas/FasL pathway will result in defect of peripheral autoreactive 
lymphocyte elimination that occurs through Fas-mediated apoptosis (144). 
However, in humans, Fas or FasL gene defects only cause the 
lymphoproliferative syndrome (ALPS) (140,145) with rare autoimmune 
manifestations (146). Most SLE patients do not have abnormality in their 
Fas/FasL gene structure and expression (147,148,149). Only sFas levels 
relate to SLE activity (150,151). Otherwise, apoptosis of peripheral 
lymphocytes in SLE patients is not compromised or even enhanced 
(152,153). This suggests that the relationship between apoptosis and 
self-tolerance in humans is much more complex than in mouse.   
Apoptotic cells may also expose intracellular and cryptic epitopes to the 
immune system (154). The degradation and modification of cellular 
constituents during apoptosis could induce immunogenicity (155,156). If 
apoptotic residues can not be cleared in due time, e.g., due to deficiencies 
in complement factors or CD14 ( 157 , 158 ), autoimmunity may be 
stimulated. 
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2-3. Mouse models of SLE 
Although no single animal model perfectly recapitulates human SLE, some 
animal models can help us understand the etiology and pathogenesis of this 
disease. There are many inbred strains of spontaneous SLE-prone mice, 
including MRL/lpr, MRL/gld, NZB (New Zealand Black), F1 hybrids of 
NZB×NZW (New Zealand White) (B/W F1), and BXSB mice. Each of 
these have their own genetic background and autoimmune characteristics 
(table 1). More gene manipulated models are being generated, such as 
transgenic or gene knockout mice, which may help clarify the significance 
of target molecules in SLE. 
 
Strain  Photo-dermatitis Histopathologic features  
  Sensitivity Igs at DEJ IC-GN Arteritis Arthritis
NZB - + + (IgM) + - - 
NZB/KN + (alopecia) unknown + (IgM) + - + 
B/W F1 - + ++ (IgG) +++ - - 
MRL/lpr ++ +++ + (IgG) +++ + + 
MRL/n ++ (aged) - + (ANA) + + + 
BXSB - ++ + (IgG) +++ - - 
Table 1. Characteristics of lupus-prone mouse strains (source: ref.159) 
Igs at DEJ: immunoglobulins deposits at the dermoepidermal junction;  
IC-GN: immune complex glomerulonephritis;  
ANA: epidermal nuclear staining. 
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2-4. Clinical features of SLE 
2-4-1. Symptoms  
The clinical course and outcome of SLE are extremely variable. 
Glomerulonephritis, arthritis, systemic small arteries vasculitis, rashes, 
haemolytic anemia and thrombocytopenia, which are caused by immune 
complexes deposition and/or autoantibody-induced ADCC, are the most 
common clinical symptoms of SLE. 
 
2-4-2. Diagnosis 
The American College of Rheumatology (ACR) classification criteria, a 
generally-accepted diagnostic standard, were devised in 1982 and revised 
in 1997 (160). Any combination of 4 or more of the following 11 criteria, 
well-documented at any time during a patient's history, makes it likely that 
the patient has SLE (specificity and sensitivity are 95% and 75%, 
respectively). 
1. Malar rash: fixed erythema, flat or raised, over the malar eminences;  
2. Discoid rash: erythematous circular raised patches with adherent 
keratotic scaling and follicular plugging; atrophic scarring may occur;  
3. Photosensitivity: exposure to ultraviolet light causes rash;  
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4. Oral ulcers: includes oral and nasopharyngeal ulcers, observed by a 
physician;  
5. Arthritis: nonerosive arthritis of two or more peripheral joints, with 
tenderness, swelling, or effusion;  
6. Serositis: pleuritis or pericarditis documented by ECG or rub or 
evidence of effusion;  
7. Renal disorder: proteinuria >0.5 g/d or 3+, or cellular casts;  
8. Neurologic disorder: seizures or psychosis without other causes;  
9. Hematologic disorder: hemolytic anemia or leukopenia (<4000/L) or 
lymphopenia (<1500/L) or thrombocytopenia (<100,000/L) in the absence 
of offending drugs;  
10. Immunologic disorder: anti-dsDNA, anti-Sm, and/or anti-phospholipid;  
11. Antinuclear antibodies: an abnormal titer of ANA by 
immunofluorescence or an equivalent assay at any point in time in the 
absence of drugs known to induce ANAs.  
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2-4-3. Therapy 
In the absence of specific therapy aiming at the pathogenesis, successful 
therapy of SLE depends on treating both underlying inflammation and 
symptoms. Currently immunosuppression is the major SLE therapy 
available. Four main classes of drugs, i.e., corticosteroids, non-steroidal 
anti-inflammatory drugs (NSAIDs), antimalarials and cytotoxic agents, are 
used.  
High doses of corticosteroids remain the first line of treatment for many 
manifestations of SLE, especially in severe disease with renal, CNS and 
hematological involement. But it causes many hazardous side effects, such 
as infection, hyperlipidaemia, hypertension, osteoporosis, diabetes, and 
insomnia (161). The combined use of NSAIDs, antimalarials and cytotoxic 
agents can reduce the steroids’ dosage and side effects to a relative low 
level.  
Antimalarials are commonly employed to treat patients with fatigue, 
arthralgia/arthritis and rash, but without major organ damage. Antimalarials 
can interfere with immune cellular functions, affect immune responses, and 
modulate cytokine levels in SLE patients. Antimalarials also improve skin 
lesions against the damaging effects of ultraviolet light. In these ways, 
antimalarials have the potential to keep SLE in remission.  
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Active lupus with major organ involvement often requires prompt, 
aggressive therapy with cytotoxic agents. Cytotoxic agents were primarily 
known to interrupt nucleic acid and protein synthesis in malignant cell.  
Then its immune inhibition was discovered. The use of cytotoxic agents in 
SLE benefits controlling active disease, reducing the rate of disease flares, 
and reducing steroid requirements.  
Currently, there are many new treatments under investigation (162). Some 
biological agents (e.g., antibodies) have been tested in clinical trials. They 
either modulate or inhibit T-cell activation, T- and B-cell interactions, 
anti-dsDNA antibody production, immune complexes deposition, 
complement activation/deposition, and cytokine activity. A hormonal 
modulator, DHEA, has also shown promising therapeutic effect in SLE 
patients. In addition, a small number of very severe refractory lupus 
patients (7 cases) received high-dose chemotherapy and autologous stem 
cell transplantation to gain remission (163). 
Other than pharmacological treatment, management of daily life can help 
SLE patients to control the disease. These therapies include avoiding 
sunlight over-exposure, low saturated fat and a high fish oil diet, stress 
avoidance, and smoking cessation. 
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2-4-4. Prognosis  
In many countries, the survival rate of SLE exceeded 80-90% in 5 years 
post-diagnosis, but decreases to 60-80% in next 10 years (164,165, 
166,167). The major causes of mortality are organ failure (especially renal 
failure), thrombocytopenia, cardiovascular diseases, infections, high SLE 
disease activity index (SLEDAI) (165,168). Proper and timely treatment in 
experienced hospitals is very important to improve the long-term survival 
rate (169). 
 
SLE is a common chronic disease that seriously imperils the survival and 
life quality of patients. There is no cure due to the ambiguous etiology. 
Investigation of SLE pathogenesis will help us to develop specific 
treatments. 
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 3. Diabetes Mellitus 
 
Diabetes mellitus is a syndrome (includes excessive urine production, 
increased fluid and food intake, body weight loss, changes in energy 
metabolism, even blurred vision and renal failure) as results of abnormal 
high blood glucose levels. This metabolism disorder has two most common 
forms: type 1 diabetes mellitus (T1DM) is caused by insufficient insulin 
production that mainly follows after autoimmune damage to pancreatic 
islets; type 2 diabetes mellitus (T2DM) is caused by failed response to 
insulin in effective organ (such as liver and muscle), but the level of insulin 
are normal or even elevated before the late stage of the disease. Besides, 
some pregnant women may suffer gestational diabetes mellitus due to 
carbohydrate intolerance. 
 
3-1. The Epidemiology of Diabetes Mellitus  
Nowadays, more than 170 million people live with diabetes worldwide 
(170), and that number will double in the next 20 years (171) (Fig. 5).  
T1DM is one of the most common chronic childhood disease whose 
incidence is about 20 to 30 per 100 000 children per year in the United 
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Kingdom, Finland, Norway and Sweden, but is much lower in Asian, 
Indian, Middle Eastern and African populations (172,173). The incidence 
of T1DM is increasing rapidly worldwide, and is estimated to exceed 
30-50 per 100,000 a year by 2010 (173). Studies showed 2.5-3% annual 
global increase rate of incidence of T1DM with a larger increase in some 
central and eastern European countries, some Asian countries and Australia 
(174,175). The largest rate of increase was seen in 0-4 year old children 
(173). 
T2DM usually occurs after the age of 30, but it can exist without any 
symptoms for many years. The first diagnosis is sometimes made through 
incidental abnormal blood or urine glucose tests, or through associated 
complications (176). It constitutes more than 90% of overall diabetes cases 
in the world (177) with large geographical prevalence variation, even 
within the same or similar ethnic groups (178,179). The greatest increase 
of T2DM is in the developing countries of Asia, Africa, and South 
America, which are evolving with rapid cultural and social changes, ageing 
populations, urbanization, and unhealthy lifestyle and behavioral patterns 
(180). Another worrisome T2DM increase is in children and adolescents. 
The proportion of T2DM in new-onset diabetes during children and 
adolescents has increased more than 15 folds (<3% vs. 45%) in last 15 
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years (181). The increase of T2DM incidence closely parallels the increase 
of obesity. This unprecedented twin epidemic is termed as "diabesity" 
(171).  
 
 
 
Figure 5.  The geographic distribution of DM prevalence  
(source: http://www.eatlas.idf.org/atlas.html?id=0） 
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3-2. The pathoaetiology of Diabetes Mellitus 
T1DM had been defined as “insulin-dependent diabetes mellitus” due to 
the insufficient insulin in the body and the necessary treatment by artificial 
insulin even in its earliest stage.  It is also called "juvenile diabetes" 
sometimes, because its onset is mainly in childhood although a few cases 
occur in adulthood, which is also called latent autoimmune diabetes of 
adults (182). T-cell-mediated autoimmune attack to the beta-cells of 
Langerhans islets is believed to be the major cause of the disease (Fig 6).  
 
Fig. 6 The pathogenesis of T1DM. (source: ref. 183) 
β-cell antigen is presented on the cell surface by MHC class I molecule. CD8+ T cells recognize this 
antigen and damage β-cell through the secretion of INF-  or TNF/TRAIL or the perforin/granzyme 
system. The dendritic cells in islets take up cell components from dead β-cells, and present them to 
CD4+ T cells in lymph nodes. Active CD4+ T cells move into the islets to mediate killing through 
the Fas/FasL pathway.  
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T2DM was called “non-insulin-dependent diabetes” in contrast to T1DM. 
A deficient reaction to insulin in liver and muscle initiates this disease. In 
these tissues, glucose processing is compromised. Thereafter, unprocessed 
glucose accumulates in circulation and reduces islet beta cells’ response to 
glucose (Fig7). T2DM patients are not ketosis-prone and do not depend on 
exogenous insulin. However, they may need insulin treatment to control 
hyperglycemia if the diet and /or oral hypoglycemic agents do not work 
well. 
 
Figure 7.  Pathophysiology of T2DM (source: ref. 170) 
A variety of factors contribute to insulin resistance. Compromise of insulin action in major target 
tissues leads to increased circulating free fatty acids and hyperglycaemia, which will impair β-cell 
viability and worsen insulin resistance. 
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Like systemic lupus erythematosus, a combination of hereditary and 
environmental factors causes these metabolism dysfunctions, either in 
T1DM or T2DM. Clinical trials show that the concordance rates of 
monozygotic twins are around 50% in both T1DM and T2DM 
(184,185,186). These results suggest that the genetic factor is not the only 
protagonist in the etiology of DM. In other words, the trigger by 
environmental factors is also necessary to diabetes onset. T2DM seems to 
be familial (187,188). In addition to genetic factors, a similar lifestyle of 
members in the same family may also play a role. 
 
3-2-1. Genetic Factors  
Most diabetes, both T1DM and T2DM, are polygenic. There are only 1-5% 
cases (mainly neonatal diabetes mellitus and maturity-onset diabetes of the 
young) that are due to monogenic mutations (189). Although there are 
many diabetes risk genes, which have been identified by different studies, 
only a few of these findings are confirmed, i.e., HLA-DQ8 and DQ2, 
MICA-5 (MHC class I chain-related genes allele 5), KIR (killer 
immunoglobulin- like receptors) (190), CTLA4 (cytotoxic lymphocyte 
antigen 4), LYP (Lymphoid tyrosine phosphatase)/PTPN22 ( 191 ) to 
T1DM; TCF7L2  (Transcription Factor 7-Like 2) ( 192 ), CAPN10 
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(calpain 10) (193), PPARG (peroxisome proliferator-activated receptor 
gamma), KCNJ11 (194,195) to T2DM. As obesity contributes to T2DM, 
genes involved in obesity should also be considered risk factors for T2DM. 
More than 22 genes, which encode members of the leptin–melanocortin 
pathway, proinflammatory cytokines and uncoupling proteins (UCPs), are 
related to obesity risks (196). 
 
3-2-2. Environmental Factors 
Various environmental factors can influence diabetes morbidity. 
 
a. Viral infection: 
T1DM pathogenesis somewhat relates virus infection. Many viruses can 
trigger cell damaging processes in their host, such as Coxsackie B virus, 
mumps, echovirus, cytomegalovirus, Epstein-Barr virus (EBV), some 
retrovirus, rotavirus, parvovirus B19 and rubella virus (197). These viruses 
can induce autoimmunity through 1) direct infection of islets (198), 2) 
molecular mimicry, i.e., viral protein sharing similar peptide sequences 
with cellular autoantigens (199), or 3) activation of innate immunity (200). 
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b. Environmental contaminants and chemicals: 
The increase of contaminants in the environment or occupational contact of 
certain chemicals could be potential risk factors of DM. For T1DM, higher 
intake of nitrates, nitrites, and N-nitroso compounds, as well as higher 
serum levels of polychlorinated biphenyls seem to link to higher incidence  
(201,202,203,204,205). Arsenic and 2,3,7,8-tetrachlorodibenzo-p-dioxin 
exposure is directly associated with T2DM risks (206,207,208,209).  
 
c. Lifestyle and social factors: 
Human behavior largely influences the incidence of DM (210). Decreased 
breastfeeding and early exposure to dietary cow-milk/cereals will raise the 
future risk of T1DM in the infants (211,212), while early supplement of 
vitamin D can decrease T1DM risks (213). The “Westernized food”, or 
energy-dense food, contributes to obesity, thereby increases the risk of 
T2DM (214). Physical activity is another effective behavior factor. Regular 
physical activity can reduce the risk of T2DM by 15-60% (195). 
Socio-economic and psychosocial factors could also indirectly affect the 
prevalence of DM through the change of lifestyle, nutrition, and natural 
environment (197,215,216).    
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d. Perinatal factors and postnatal growth: 
Perinatal factors associated with increased T1DM risk to infant may 
include older maternal age at birth (217), excessive maternal weight gain, 
amniocentesis, preeclampsia (218), cesarean section delivery, complicated 
delivery, and maternal-fetal blood group incompatibility (219,220). Size at 
birth and early postnatal growth rates, which may reflects the fetal 
nutritional conditions, are significantly associated with the risk of diabetes, 
both T1DM and T2DM (221,222,223). 
 
3-2-3. Accelerator hypothesis  
Recent evidences indicate that incidence of both T1DM and T2DM 
increase in parallel with obesity (224,225). Meanwhile, the important role 
of insulin resistance in the early stages of T1DM development has been 
widely accepted (226,227). These findings led to a new theory called 
“accelerator hypothesis”. This hypothesis proposes that “T1DM and 
T2DM are the same disorder of insulin resistance set against different 
genetic backgrounds” (228). Excess bodyweight is the central point to the 
development of diabetes, both T1DM and T2DM. Weight gain increases 
insulin resistance and consequently results in hyperglycemia. Long-term 
high blood glucose induces apoptosis and immunogenicity of beta cells. 
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Based on these pathological changes, individual gene polymorphism and 
constitution, determine the tempo of beta cell loss and the age of onset, i.e., 
the manifestation of T1DM or T2DM. This hypothesis deems that T1DM 
and T2DM are subsets of the same disease. Thus, control of weight gain 
could prevent DM by slowing its progress. 
 
3-3. The clinical features of DM 
3-3-1. Symptoms and complications 
Hyperglycemia is the principal cause of diabetes symptoms and 
complications. The classical diabetes triad symptoms are polyuria, 
polydipsia and polyphagia, i.e., frequent urination, increased thirst and 
fluid intake, increased appetite. Symptoms may develop quite rapidly 
(weeks or months) in T1DM, particularly in children. T1DM may also 
cause rapid weight loss and implacable fatigue. However, symptoms 
usually develop much slowly and mildly, sometimes may be even absent, 
in T2DM.  
Ketoacidosis (DKA), an extreme state of metabolic dysregulation, may be 
the most common acute complication of DM. It is characterized by the 
acetone smell in the patient's breath, Kussmaul breathing, polyuria, nausea, 
vomiting and abdominal pain, and psychological disturbance. Severe DKA 
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can cause coma and even death (229). It is mainly present in patients with 
T1DM, but also observed in patients with T2DM under certain conditions. 
Another serious acute complication is hyperosmolar nonketotic state, 
which is more common in T2DM (230). It is mainly the result of 
dehydration due to loss of body water.  
Prolonged high blood glucose levels along with abnormal lipid levels lead 
to blood vessels lesion (angiopathy), which subsequently induces chronic 
multiple organ complications, including blindness, renal failure, lower 
limb gangrene and cardiovascular diseases. 
Nosogenetic effects of hyperglycemia mainly attribute to the formation of 
advanced glycation end-products (AGEs). Hyperglycemia in diabetes 
increases the formation and accumulation of AGEs. AGEs can interact 
with cell-surface receptor of AGE (RAGE), leading to cell activation and 
increasing expression of extracellular matrix proteins, vascular adhesion 
molecules, cytokines, growth factors, and the generation of reactive 
oxygen intermediates. Moreover, certain AGEs precursor can covalently 
crosslink proteins and change their structure and function. These 
pathologic changes result in almost all the diabetes complications, both 
micro- and macroangiopathies. 
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3-3-2. Diagnosis 
The diagnostic criteria are based on the WHO recommendations of 1999. 
They incorporate both fasting criterion and 2-h-after-glucose-load (oral 
glucose tolerance test (OGTT)) criterion into a practicable diagnostic 
classification (table 2) (231). About 7% of people with impaired fasting 
glucose and impaired glucose tolerance will eventually progress to overt 
diabetes every year without proper treatment (232,233). If a pregnant 
woman has any two of the followings, she will be diagnosed as gestational 
diabetes: 1) fasting plasma glucose more than 5.3 mmol/dl, 2) 1-hour 
glucose level of OGTT more than 10 mmol/dl, 3) 2-hour glucose level of 
OGTT more than 8.6 mmol/dl (234).  
There are some other accessorial clinical tests to value the status of DM. 
For examples, urine ketones test can indicate the severity of T1DM; the 
glycosylated hemoglobin test will give information about how well the 
blood glucose is controlled. 
 
Table 2. Diagnostic criteria of diabetes mellitus and other categories of hyperglycemia 
(source: ref. 231) 
Glucose load=75 g glucose orally. 
FACULTÉ  DES  ÉTUDES  SUPÉRIEURES  UNIVERSITÉ  DE  MONTRÉAL      BING HAN 40
3-3-3. Therapy 
Diabetes mellitus is a chronic disease currently without a cure. The goal of 
therapy is to maintain blood glucose level as close to normal as possible to 
prevent either acute or chronic complications.  
 
3-3-3-1. Diabetes education and lifestyle intervention 
Self-monitoring the blood glucose of diabetes patient is very important to 
keep both short-term and long-term blood glucose levels within acceptable 
bounds. Proper diet, regular physical exercise, moderate body weight and 
refrain from smoke and alcohol will help the patient to control the blood 
sugar and greatly reduce the risk of progression (232, 233). It is very 
necessary to impart related knowledge to the diabetes patients and help 
them modify their lifestyle.  
 
3-3-3-2. Insulin and other medications 
T1DM patients, as well as T2DM patients who do not respond to oral 
medications, need insulin therapy to survive. There are several different 
insulin types and administration methods available currently.  
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Besides insulin, many choices of drugs can be used to modulate glucose 
levels, especially for T2DM. The mechanism and active site of these 
medications are shown in Table 3 
Additionally, since cardiovascular disorders, such as hypertension, 
coronary artery disease and cerebrovascular disease, occur very often in 
T2DM (235), the management of cardiovascular risk factors is necessary 
and beneficial (236). 
 
Classification Medication Route The way it works 
Sulfonylureas Glimepiride, 
Glipizide, Glipizide 
ER, Glyburide  
Oral Increases insulin production 
Biguanides Glucophage, 
Glucophage XR 
Oral Lowers glucose from digestion 
Alpha-Glucosidase 
Inhibitors 
Glyset and Precose Oral Slows digestion, slows glucose 
production 
Thiazolidinediones Actos and Avandia Oral Lowers glucose production 
Meglitinides Prandin and Starlix Oral Increases insulin production 
DPP-4 Inhibitors Januvia Oral Lowers glucose by blocking an 
enzyme 
Incretin Mimetics Byetta Injectable Helps the pancreas make insulin, 
slows digestion 
Anti-hyperglycemic Symlin Injectable Controls postprandial blood glucose 
 
Table 3. Medications for Diabetes (source: ref.237) 
 
 
 
FACULTÉ  DES  ÉTUDES  SUPÉRIEURES  UNIVERSITÉ  DE  MONTRÉAL      BING HAN 42
3-3-3-3. Organ and cell transplantation 
The DM, in particular T1DM, has no cure. A potential cure for it is 
transplantation, either at the organ level or cell level. 
a. Pancreas transplantation 
Pancreas transplantation is an effective treatment for diabetes mellitus, 
especially for the end-stage renal complication. It was first successfully 
performed in combination with kidney transplant in 1966 (238). The 
improvements in surgery and immunosuppressors have significantly 
increased the graft survival rate; the 5-year graft survival rate is around 
50%-70% ( 239 ). Pancreas transplant can achieve long-term 
normoglycemia, reduce mortality, and ameliorate diabetic complications 
(240). However, pancreas transplantation is still a high-risk operation with 
some severe postoperative complications. Moreover, the availability of 
organ donors and side effects of immunosuppressants are also limiting 
factors for popularization of this treatment.  
 
b. Islet transplantation 
Islet transplantation was applied to treat insulin-dependent diabetes since 
the 1970’s, but it had hardly achieved desirable long-term effectiveness 
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until the advent of a steroid-free immunosuppressive protocol in 2000 
(241). The adoption of the Edmonton protocol, which uses steroid-free 
immunosuppression, has elevated the success of islet transplantation 
greatly. Most recipients could attain an insulin-independence immediately 
after transplantation (242,243). However, a large islet mass (> 10,000 islet 
equivalents (IEQ)/kg recipient body weight) derived from multiple donors 
(2-4) is necessary to achieve insulin independence (244) because of the 
loss of a large number of transplanted islets in the first 10–14 days after 
transplantation despite efficient immunosuppressive regimens (245,246). 
Experimental models also show that early damage results in 60% loss of 
the transplanted syngeneic islet mass in the peri-transplant period 
(247,248). This early stage non-rejective graft failure or the primary 
non-function (PNF) is becoming a bottleneck for the development of islet 
transplantation since the improvement of immunosuppressive agents. PNF 
reduces effective grafted islet mass, and then increases the metabolic load 
to surviving islets. This overloading reduces islet survival time and 
diminishes the long-term insulin independence, which is frequently (~90%) 
lost in 5 years after islet transplantation (249,250).  
The reasons for PNF include oxidative stress in the islets during 
pretransplant manipulations (251,252), loss of trophic factors for the 
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isolated islets (253), host innate immunity and inflammatory responses 
( 254 ), and failure of revascularization of islet graft ( 255 , 256 ). 
Proinflammatory cytokines (e.g., TNF-α, IL-1, and IFN-γ)-triggered 
multiple signaling pathways (e.g., c-Jun NH2-terminal kinase (JNK1) 
(257), Fas/FasL (258), nuclear factor- B, and transcription factor signal 
transducer and activator of transcription (STAT) (259)) contribute to the 
occurrence of PNF. Prevention of islet graft PNF through improvement of 
islet isolation and culture technology, application of inflammation 
inhibitors, and genetic modification to repress islet apoptosis would likely 
make a significant impact on the efficacy of islet transplantation.   
 
c. Stem cell transplantation 
Recent research showed that embryonic, fetal and adult stem/progenitor 
cells including putative multipotent pancreatic stem/progenitor cells have a 
potential for self-renewal of islet β-cells (260,261). The transplantation of 
insulin-producing β-cell derived from either wild-type or genetically 
modified stem/progenitor cells, or the expansion and differentiation of 
putative multipotent pancreatic stem/progenitor cells in vivo, may be 
promising alternative therapies for T1DM or T2DM in humans.  
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3-3-3-4. Gene therapy 
Gene therapy of DM has been under investigation intensely in recent years. 
Studies include genetic modification of graft islets, genetically engineered 
ectopic insulin production, preventing or curing autoimmunity (262). All 
these therapies require an effective gene delivery system, which is the 
bottleneck of the gene therapy. The disadvantages (such as oncogenicity, 
efficacy and immunogenicity) of viral gene delivery systems limit its 
clinical usefulness. With future advances in gene delivery technologies, 
gene therapy may be a potential cure to DM. 
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Hypothesis and Objective 
The etiology of SLE remains unclear. Disorder of lymphocyte apoptosis 
can lead to lupus-like syndromes in mouse models. But in humans, the 
relationship between SLE and lymphocyte apoptosis is a puzzle. DcR3, a 
native block of apoptosis, may play a role in pathogenesis of human SLE 
via interruption of lymphocyte apoptosis.  
Our group pioneered the research on the biological functions of DcR3. We 
discovered its roles in the modulation of T-lymphocyte functions (7,55) 
and reported its expression in varied malignant tumors (17). Moreover, we 
showed protective effect of DcR3 on islet transplantation (53).  
As part of my Ph.D. Program, the important- role of DcR3 in the 
pathogenesis of SLE both in a mouse model and in patients has been 
investigated. The mechanisms of DcR3’s effect on islet protection have 
been further studied. The details are provided in the following 3 chapters.    
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Article 1. 
Overexpression of human decoy receptor 3 in mice results in 
a systemic lupus erythematosus-like syndrome 
Bing Han , Paul A. Moore, Jiangping Wu , Hongyu Luo   
 
Arthritis Rheum. 56(11):3748-58, 2007.  
 
Summary: In this paper, we showed that overexpression of DcR3 induced 
lupus-like syndromes in transgenic mouse model. We also found enlarged 
memory T cell pool in DcR3 transgenic mouse. Furthermore, we 
demonstrated that DcR3 could disturb AICD of T lymphocytes.  Our 
results imply that DcR3 may play an important role in SLE pathogenesis 
through interfering lymphocyte homostasis. 
 
 
Bing Han performed all assays and experiments, and processed and 
analyzed data; Paul Moore constructed DcR3 plasmid and synthesized 
recombinant DcR3; Jiangping Wu and Hongyu Luo directed the 
experiment design and data analysis.
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ABSTRACT 
 
Objective 
Decoy receptor 3 (DcR3), a tumor necrosis factor receptor family member, 
is a secreted protein that can enhance cell survival by interfering with 
multiple apoptosis pathways. This study was undertaken to investigate the 
role of DcR3 in the pathogenesis of autoimmune disease. 
 
Methods 
We generated transgenic mice with actin promoter-driven expression of 
human DcR3 and investigated the development of autoimmune disease in 
these mice. 
 
Results 
T cell immune responses were compromised in young DcR3-transgenic 
mice. Beyond 5-6 months of age, transgenic mice developed a systemic 
lupus erythematosus (SLE)-like syndrome, with numerous features of the 
disease. They produced autoantibodies against double-stranded DNA. 
Their kidneys showed pathologic changes indicative of glomerular 
nephritis and IgG and C3 deposition, and proteinuria, leukocyturia, and 
hematuria, were evident. Aged transgenic mice also developed skin lesions 
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and lymphocyte infiltration in the liver, and exhibited leukopenia, anemia, 
and thrombocytopenia. The SLE-like syndrome penetrance in 
DcR3-transgenic mice was sex associated, occurring in 60% of females 
versus 20% of males. Exogenous recombinant DcR3 or endogenous DcR3 
produced by transgenic T cells effectively protected T cells against 
activation-induced apoptosis in vitro. Probably as a consequence of this, 
CD4 cells with a phenotype of previous activation were increased in the 
peripheral blood of transgenic mice beyond 6 months of age. 
 
Conclusion 
These results show that DcR3 overexpression could lead to an SLE-like 
syndrome in mice. 
FACULTÉ  DES  ÉTUDES  SUPÉRIEURES  UNIVERSITÉ  DE  MONTRÉAL        BING HAN 71
Systemic lupus erythematosus (SLE) is a potentially severe autoimmune 
disease of undetermined etiology, with genetic, environmental, and sex 
factors as contributing elements. It is a polygenic disease, and as many as 
30 susceptibility loci with possible links to its pathogenesis have been 
identified in mice (1). Among suspected pathogenic genes, a sizable 
number are in the apoptosis pathway (2). Indeed, in prototypical murine 
SLE models (i.e., lpr/lpr and gld/gld mice), the animals are defective in 
Fas and FasL, respectively, which are critical elements in T cell apoptosis. 
In contrast, SLE patients rarely have Fas or FasL mutations (3,4). This 
prompted us to examine other genes in the apoptosis pathway, with regard 
to their roles in SLE pathogenesis. 
Human decoy receptor 3 (DcR3) belongs to the tumor necrosis factor 
receptor (TNFR) family (5), but lacks transmembrane and cytoplasmic 
domains in its sequence. It is thus a secreted protein (6). DcR3 can bind to 
the TNF family members FasL (5), LIGHT (6,7), and TNF-like molecule 
1A (TL1A) (8) and block their interaction with their respective receptors, 
i.e., Fas, herpesvirus entry mediator (HVEM) protein, and the death 
domain-containing receptor DR3 (6-8). DcR3 does not bind to other 
known TNF family members (9), but findings of one study have suggested 
the existence of additional DcR3-binding ligand(s) (10). The mouse does 
not have an orthologous counterpart of the human DcR3 gene according to 
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a genome-wide computer search, but studies by our group and by Bossen 
et al have established that human DcR3 can bind to mouse FasL and 
LIGHT (6,9,11). This allows human DcR3 to function in mouse models, 
both in vitro and in vivo. 
DcR3 has a clear role in apoptosis. FasL is a well-known molecule 
involved in apoptosis. LIGHT is a ligand for HVEM protein and 
lymphotoxin receptor (LT R), in addition to being a ligand for DcR3 (12). 
LIGHT can induce apoptosis in cells expressing both HVEM protein and 
LT R (13) or LT R alone (14). TL1A, a newly recognized member of the 
TNF family, can evoke apoptosis via its receptor, DR3 (8). Consequently, 
the interaction of DcR3 with FasL, LIGHT, and TL1A blocks apoptosis 
mediated by Fas, HVEM protein, LT R, and DR3 (8). 
Normal T cells express low levels of DcR3 (15), and healthy individuals 
have near-background serum DcR3 levels (16). DcR3 expression is 
augmented in activated T cells (15); this probably represents a fine-tuning 
mechanism to balance the need for clonal expansion and subsequent 
massive activation-induced cell death (AICD) of T cells. Malfunction of 
this balance due to failed AICD might lead to pathologic consequences, 
such as autoimmune diseases, including SLE. Of interest, overexpression 
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of DcR3 messenger RNA in peripheral blood mononuclear cells (PBMCs) 
of SLE patients compared with healthy individuals has been reported (17). 
In this study, to explore the possible role of DcR3 in SLE pathogenesis, we 
generated transgenic mice with actin promoter-driven expression of human 
DcR3. These DcR3-transgenic mice manifested an SLE-like syndrome 
after 5-6 months of age. 
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MATERIALS AND METHODS 
 
Generation of transgenic mice with actin promoter-driven DcR3 
expression. 
Human full-length DcR3 complementary DNA (cDNA) was cloned into 
Bam HI and Xba I sites in pAC vector between the human -actin 
promoter and -actin poly(A) signals. The resulting construct was named 
pAC-DcR3. The 5.7-kb Cla I/Cla I fragment containing the -actin 
promoter, DcR3 cDNA, and -actin poly(A) signal was excised and 
injected into fertilized eggs from C3H × C57BL/6 mice or C57BL/6 mice. 
The transgenic mice were genotyped by polymerase chain reaction (PCR), 
for which the 5  primer (5 -GAGCGCTTCCTCCCTGTGCAC) was 
derived from the DcR3 sequence and the 3  primer (5
-GAATGCAATTGTTGTTGGTAACTTG) from the actin sequence 
downstream of DcR3. Amplification conditions were as follows: 1 cycle of 
94°C for 5 minutes, 30 cycles of 94°C for 30 seconds, 58°C for 30 seconds, 
and 72°C for 30 seconds, and 1 cycle of 72°C for 5 minutes. The PCR 
results were confirmed by enzyme-linked immunosorbent assay (ELISA) 
for serum DcR3. 
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DcR3 ELISA. 
The DcR3 ELISA has been described elsewhere (16). A monoclonal 
antibody specific for DcR3 was used for coating, and a biotinylated 
affinity-purified rabbit antibody against DcR3 was used as the detecting 
antibody. The sensitivity of the assay was 6 pg/ml. 
Flow cytometry. 
Two- or 3-color flow cytometry was performed to determine the 
expression of Thy1.2, CD4, CD8, CD3, T cell receptor (TCR ), CD62L, 
CD44, CD19, CD5, CD25, and annexin V, as described previously (18). 
Western blotting to detect serum autoantibodies against various 
organs. 
The organs were homogenized in phosphate buffered saline (PBS) and 
centrifuged for 15 minutes at 3,000g. The cleared lysates were passed 
through a 0.22- m microfilter and resolved by sodium dodecyl sulfate-8% 
polyacrylamide gel electrophoreses (60 g/lane) overnight at 20V. The 
proteins were transferred to polyvinylidene difluoride membranes, which 
were then blocked with Tris buffered saline (TBS) blocking buffer (100 
mM Tris·ECl, 0.9% NaCl [pH 7.5]) containing 5% milk powder. The 
membranes were reacted with transgenic or wild-type mouse serum (1:500 
dilution in blocking buffer) overnight at 4°C and washed 3 times at room 
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temperature with TBS containing 0.05% Tween 20. Autoantibody was 
detected with sheep anti-mouse IgG (1:2,000 dilution; Amersham 
Biosciences, Baie d'Urfé, Quebec, Canada) followed by enhanced 
chemiluminescence. 
Immunofluorescence for detection of antinuclear antibodies. 
HeLa cells were fixed at 4°C for 60 minutes using a Cytofix/Cytoperm kit 
(BD Biosciences, San Diego, CA) and then incubated overnight at 4°C 
with wild-type or transgenic mouse serum (1:500 dilution in the wash 
buffer from the kit). After washing, the cells were reacted with fluorescein 
isothiocyanate-conjugated goat anti-mouse IgG antibody (1:1,000 dilution; 
Bethyl Laboratories, Montgomery, TX) overnight at 4°C. The cells were 
examined under a fluorescence microscope. 
ELISA for anti-double-stranded DNA (anti-dsDNA) antibodies. 
Ninety-six-well high-affinity ELISA microplates (Costar, Cambridge, MA) 
were coated with 250 g/ml salmon sperm DNA (Invitrogen, Burlington, 
Ontario, Canada) in coating buffer (0.05M sodium bicarbonate solution 
[pH 9.5]) overnight at 4°C. After washing with PBS containing 0.05% 
Tween 20, the plates were incubated with blocking buffer (PBS containing 
1% bovine serum albumin) for 1 hour at room temperature. Wild-type and 
transgenic mouse sera were diluted in blocking buffer at 1:50 and 
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incubated overnight in the wells at 4°C. After washing, the plates were 
reacted with horseradish peroxidase-conjugated sheep anti-mouse IgG 
antibody (1:2,000 dilution; Amersham Biosciences) for 1 hour at room 
temperature. Signals were revealed by addition of tetramethylbenzidine 
substrate (BD Biosciences), followed by 20-minute incubation at room 
temperature. The reaction was stopped using 50 l 4N HCl, and the plates 
were read at a wavelength of 450 nm. 
Detection of leukocytes, protein, and hemoglobin in urine. 
Chemstrip (Roche, Laval, Quebec, Canada) was used for semiquantitative 
analysis of leukocytes, protein, and hemoglobin in urine. 
T cell culture and apoptosis. 
Spleen cells were isolated as described previously (18). In some 
experiments, the cells were cultured with crosslinked FasL-FLAG for 24 
hours in the presence or absence of various concentrations of soluble DcR3 
(0.133 mg/ml FasL-FLAG was preincubated for 24 hours at 4°C at a 1:1 
ratio with 0.133 mg/ml mouse monoclonal antibody against FLAG; the 
final concentration of crosslinked FasL-FLAG for culture was 0.6 g/ml). 
In other experiments, T cells were first activated for 48 hours with soluble 
anti-CD3 (2 g/ml). The cells were washed and recultured for 48 hours in 
the presence of 50 units/ml interleukin-2 (IL-2); they were then washed 
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again, transferred to new wells coated with anti-CD3 (10 g/ml during 
coating), and coated for an additional 48 hours in the presence or absence 
of DcR3 at various concentrations. CD4 and CD8 cell apoptosis was 
analyzed by annexin V staining on CD4- or CD8-gated cells on 2-color 
flow cytometry (18). 
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RESULTS 
 
DcR3-transgenic mice. 
DcR3-transgenic mice were generated on both the C3H × C57BL/6 and the 
C57BL/6 backgrounds, using the human -actin promoter. The transgenic 
construct pAC-DcR3 is shown in Figure 1A. Seven founders were 
identified by PCR of tail DNA. PCR results in line 754 (C3H × C57BL/6 
background) and line 17139 (C57BL/6 background) are illustrated in 
Figure 1B. The results were confirmed by detection of DcR3 in serum. 
DcR3 was found in levels ranging from 20 ng/ml to 80 ng/ml in serum 
from transgenic mice, but was absent in wild-type littermates (Figure 1C). 
Most of the results presented herein were from line 754 (backcrossed to 
C57BL/6 for 5-8 generations), but line17139 (pure C57BL/6 background) 
exhibited a similar phenotype, such as lymphadenopathy, pathologic 
findings in the kidney, liver and skin, and shortened lifespan in females) 
(data not shown). Spleen T cells from transgenic mice were able to secrete 
high concentrations of DcR3 ( 10 ng/ml) into culture supernatants within 
48 hours (Figure 1D).  
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DcR3-transgenic mice were fertile, with no gross anomalies observed 
before 4-6 months of age. In transgenic mice younger than 5-6 months of 
age, thymus, spleen, and lymph node weight and cellularity were in the 
normal range, as were cell subpopulations in these organs (data not shown). 
Their T cell proliferation response to solid-phase anti-CD3 alone or to 
anti-CD3 plus anti-CD28 was variable and did not show consistent changes 
in comparison with T cells from wild-type mice, but they exhibited 
increased secretion of IL-4 (but not interferon- ) (data not shown). 
Transgenic and wild-type mice had similar levels of IgA, IgM, IgG2A, and 
IgG3, but transgenic mice produced higher amounts of IgG1 and IgG2b 
than did wild-type mice. Transgenic mice also generated significantly 
higher concentrations of IgE, a typical Th2-dependent isotype, between 2 
months and 6 months of age (data not shown). The IgG1 and IgE 
overproduction indicated that immune responses in transgenic mice were 
skewed toward a Th2-type response. Delayed-type hypersensitivity in 
transgenic mice was compromised compared with that in wild-type mice 
(data not shown); augmented Th2-type responses might have been 
responsible, at least in part, for this. 
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Lymphadenopathy and lifespan of DcR3-transgenic mice. 
After age 4-6 months, DcR3-transgenic mice developed lymphadenopathy 
(defined as cervical lymph node weight >20 mg), with a higher penetrance 
in females (64.5%) than in males (20%) (Figures 2A and B). In 90% of 
cases, the lymphadenopathy was accompanied by splenomegaly (defined 
as spleen weight >1.5-fold the mean normal spleen weight) (Figure 2C); in 
contrast, the spleens of transgenic mice without lymphadenopathy did not 
differ in size from those of their wild-type littermates (results not shown). 
A large percentage of cells in the enlarged lymph nodes (51.6%) were 
Thy1.2+ T cells, among which 62.9% were CD4-,CD8- double negative 
(Figure 2D). In 3 randomly selected transgenic mice, the absolute number 
of this double-negative population in the cervical lymph nodes was 252 ± 
85 × 106 cells (mean ± SD), while the CD4+ population was 68 ± 23 × 106 
cells and the CD8+ population was 50 ± 17 × 106 cells in these nodes. 
Unusually, a large percentage of T cells (Thy1.2+, CD3+, TCR +, CD8-, 
and predominantly CD4-) from the lymph nodes (57.6%) expressed a B 
cell marker (B220) (Figure 2E) and were CD44+ and CD62Lhigh. Such 
lymphadenopathy and the unusual phenotype of cells (B220+ 
double-negative T cells) in the enlarged lymph nodes were similar to 
findings in lpr/lpr mice, which have a defective Fas-mediated apoptosis 
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pathway (19), although the phenotype occurred at an older age in our 
DcR3-transgenic mice (>5-6 months versus 2 months).  
The lifespan of DcR3-transgenic mice was shortened, especially in females 
and those with lymphadenopathy, compared with that of wild-type mice 
(Figure 2F). Among female DcR3-transgenic mice, the 14-month survival 
rate was 63.2%, and among male transgenic mice, it was 81.8%. Among 
transgenic mice that died before 14 months of age (n = 11), the majority 
(>80%) had lymphadenopathy. This lifespan was, however, longer than 
that of C57BL/6-lpr/lpr mice (mean ± SD lifespan 10.1 ± 0.5 months in 
females [20]). 
Development of an SLE-like syndrome after 6 months of age in 
DcR3-transgenic mice. 
Various immunologic parameters were evaluated in mice >6 months old. 
In immunoblotting studies in which extracts from self tissues were used as 
antigens and self sera were used as antibodies, we evaluated the presence 
of serum autoantibodies against self tissue. Transgenic mice clearly 
expressed autoantibodies against self tissue (Figure 3A). It should be noted 
that in general, not all antibodies are effective in immunoblotting. 
Therefore, the bands shown in Figure 3A probably represent a part of 
tissue antigens targeted by autoantibodies. Nevertheless, comparing the 
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results from transgenic and wild-type mice, it is clear that abundant 
autoantibodies were present in the former but not the latter. 
Transgenic mice also produced antinuclear antibodies (Figure 3B) and 
anti-dsDNA antibodies (Figure 3C), the latter being a hallmark of SLE. 
With positivity defined as 2 SD above the mean in serum from wild-type 
mice, 77% of female transgenic mice and 55% of male transgenic mice 
were found to be anti-dsDNA antibody positive, demonstrating a higher 
penetrance in females, similar to findings in human SLE. 
B-1 cells are a prominent B cell population during early ontogeny ([21]). 
In adults, B-1 cells are abundant in celomic cavities and can be classified 
into B-1a and B-1b subpopulations, which are similar in their surface 
markers, including CD11b expression, but the former is CD5+ while the 
latter is CD5- ([22]). In human SLE, the B-1a subpopulation in PBMCs is 
augmented ([23]). We demonstrated that the B-1a subpopulation was 
significantly increased in transgenic mouse PB B cells (CD19+) compared 
with wild-type mouse PB B cells (32.8% versus 11.5%) (Figure 3D). 
Consistent with this finding, the peritoneal B-1a, but not B-1b, 
subpopulation was expanded among B cells of transgenic mice (Figure 3E). 
There was no abnormal expansion of the total B cell population in the 
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PBMCs, spleen, or peritoneal cavity of transgenic mice compared with 
wild-type mice (data not shown). 
Human SLE is associated with glomerulonephritis. Thus, renal pathology 
and function were studied in DcR3-transgenic mice. Beyond age 6 months, 
the kidneys of transgenic mice had prominently enlarged glomeruli with 
increased glomerular epithelial cellularity and mesangial hypertrophy, 
along with interstitial fibrosis, as seen with hematoxylin and eosin (H&E) 
staining (Figure 4A). Leakage of red blood cells into interstitia was 
apparent. There was also obvious IgG and C3 deposition in the glomeruli 
and in interstitial spaces (Figure 4A). Semiquantitative assays of urine 
revealed leukocyturia, proteinuria, and hematuria in transgenic, but not 
wild-type, mice. This phenotype was significantly more common in 
transgenic females (Figure 4B). In the liver of DcR3-transgenic mice >6 
months of age, periarterial lymphocyte infiltration was observed (Figure 
4C), similar to the liver pathology found in SLE patients ([24]).  
Beyond age 12 months, DcR3-transgenic females frequently (40%) 
developed skin lesions, as seen in Figure 4D. Lesions in the epidermis 
exhibited superficial crusting and erosion. In the damaged areas, 
polymorphonuclear cell infiltration and hyperkeratosis of the epidermis 
with follicular plugging were apparent. The junction between the epidermis 
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and the dermis was unclear, due to the loss of epidermis pegs and the 
presence of cell infiltration. In the dermis, under the eroded lesion, 
granulomatous tissue consisting of collagen fibers, fibroblasts, and 
infiltrating lymphocytes was present. Mild edema and vasodilatation of the 
capillaries and small vessels with red blood cells were observed in the 
dermis, with clumps of infiltrating lymphocytes surrounding the vessels 
and appendages. Band-like infiltrating lymphocytes were found in some 
subcutaneous layers. The overall pathologic features were similar to those 
manifested in MRL/lpr mice ([25]), and were reminiscent of findings in 
human chronic cutaneous lupus. 
In human SLE, leukocytopenia, thrombocytopenia, and anemia are 
common ([26]). This was also the case in DcR3-transgenic mice >6 
months of age. As shown in Figure 4E, leukocytopenia occurred in 6 of 10, 
thrombocytopenia in 3 of 9, and anemia in 4 of 10 female transgenic mice, 
using the mean values minus 2 SD in wild-type mice as thresholds. Two of 
9 male transgenic mice exhibited anemia, but none of the transgenic males 
had leukocytopenia or thrombocytopenia. The frequency of these 3 
disorders in male transgenic mice did not differ significantly from that in 
wild-type mice, but the frequency of all 3 disorders was significantly 
greater in transgenic females than in wild-type mice. This again 
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demonstrates that transgenic females had more severe hematologic damage, 
similar to findings in human SLE. In transgenic mice, bone marrow did not 
have obvious abnormalities in cellularity as determined with H&E staining, 
or reduction in lineage-negative precursor cells as assessed by flow 
cytometry (results not shown). Furthermore, sera from transgenic mice did 
not contain antibodies reactive with lineage-negative precursor cells, as 
determined by immunofluorescence microscopy (results not shown). This 
suggests that the bone marrow deficiency was not the major cause of the 
observed hematologic damage in transgenic mice. 
DcR3 promotion of survival of activated T cells. 
We next investigated the mechanism by which DcR3 triggers the SLE-like 
syndrome in mice. In a normal immune response, T cell activation is 
followed by AICD, which is responsible for the shrinking of expanded T 
cell colonies. Abnormal T cell AICD is believed to be one of the factors in 
SLE pathogenesis. To assess the role of DcR3 in T cell survival after 
activation, we applied a typical model of in vitro AICD. Spleen CD4 and 
CD8 cells from wild-type and transgenic mice were first activated for 48 
hours with soluble anti-CD3, and then expanded with IL-2 for an 
additional 48 hours. When these cells were further stimulated with 
solid-phase anti-CD3, they underwent significant apoptosis, as seen in 
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Figure 5A. DcR3 is capable of blocking apoptosis pathways mediated by at 
least 4 TNFR family members, i.e., Fas, HVEM protein, LT R, and DR3 
([6-8]). We demonstrated that DcR3 continuously secreted by spleen cells 
from transgenic mice drastically inhibited CD4 cell AICD; similar 
protection of CD8 cells by DcR3 was also evident (Figure 5A). In these 
experiments, CD4 and CD8 cells from wild-type and transgenic mice were 
similarly activated, based on their CD25 expression (data not shown).  
Experiments were then performed to investigate whether the Fas pathway 
could be blocked by DcR3 during T cell apoptosis. In the absence of 
recombinant FasL, resting transgenic or wild-type mouse CD4 cells 
exhibited 19.6-24.1% background apoptosis after 16-hour culture either 
without DcR3, with 10 g/ml recombinant DcR3, or with DcR3 secreted 
de novo from transgenic mouse T cells (Figure 5B). In the presence of 
FasL, which was crosslinked to enhance its efficacy ([27]), wild-type 
mouse CD4 cells underwent massive apoptosis (52.2%) after 16-hour 
culture; this is compatible with the fact that Fas is constitutively expressed 
in resting T cells and crosslinking of Fas results in apoptosis in various cell 
types ([28]). Exogenous recombinant DcR3 at 10 g/ml almost completely 
prevented such apoptosis in wild-type mouse CD4 cells (16.3% apoptosis). 
Although DcR3 secreted de novo by CD4 cells was sufficient to 
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completely protect activated CD4 cells against death in the absence of 
exogenous FasL, as shown in Figure 5A, it became less effective (43.7% 
apoptosis), but was still consistently protective, in the presence of excess 
exogenous FasL (600 ng/ml) (Figure 5B), likely due to the relatively high 
concentration of the latter. The dose-dependent protective effect of 
exogenous recombinant DcR3 on CD4 cells is depicted in Figure 5D. A 
similar dose-dependent protective effect of exogenous or de novo-secreted 
DcR3 could also be observed in CD8 cells (Figures 5C and D). 
The above-described results demonstrate that inhibition of the 
Fas-mediated apoptosis pathway is at least one of the protective 
mechanisms used by DcR3 in promoting T cell survival. Bim, a 
proapoptotic BH3-only protein, has been implicated in clonal contraction 
due to its role in cytokine deprivation-associated cell death ([29]), and a 
recent study revealed that Fas signaling leads to Bim induction, linking the 
Fas pathway to the Bim pathway ([30]). Thus, blocking of Fas signaling by 
DcR3 not only directly affects the Fas pathway but can also indirectly 
interfere with the Bim pathway, both of which are important in clonal 
contraction. 
In a normal immune response, T cell clonal contraction follows clonal 
expansion; such contraction depends on AICD. Some T cells that 
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underwent AICD might have had a low affinity for specific antigen in the 
immune response but might cross-react with self antigen; this might 
otherwise have evoked autoimmune responses, had AICD not been taking 
place. In the peripheral blood of transgenic mice >6 months of age, a 
significantly higher percentage of CD4 cells exhibited the CD62Llow 
(73.2%) and CD44high (70.8%) phenotype, compared with CD4 cells from 
wild-type mice (33.4% and 22.7%, respectively) (Figure 6A). These cells 
represented previously but not recently activated CD4 cells, since their 
CD25 expression was low. As shown in Figures 6B and C, the percentages 
of CD44high,CD25-,CD4+ and CD44high,CD62Llow,CD4+ cells in the 
peripheral blood of DcR3-transgenic mice were significantly elevated 
compared with the percentages in wild-type mice. Among transgenic mice, 
these percentages did not differ by sex or by presence or absence of 
lymphadenopathy (data not shown). These findings, plus our 
demonstration that DcR3 protected against AICD, suggest that DcR3 might 
promote the survival of activated CD4 cells in vivo, and these surviving 
cells might be at the core of SLE pathogenesis. Nevertheless, we cannot 
exclude the possibility that such a phenomenon reflects increased 
activation, rather than decreased apoptosis, of CD4 cells in this 
autoimmune model.  
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DISCUSSION 
 
DcR3 is a death decoy protein that blocks multiple apoptosis pathways, 
including Fas/FasL. We have demonstrated that DcR3, in the form of 
either recombinant protein or protein secreted by transgenic leukocytes, 
could effectively prevent AICD of CD4 and CD8 cells. Inhibition of T cell 
death could disrupt clonal shrinkage after clonal expansion during an 
immune response, resulting in the survival of abnormal self cross-reactive 
T cells and, potentially, autoimmune disease. Indeed, failed T cell 
apoptosis is implicated in SLE pathogenesis, as shown in lpr/lpr and 
gld/gld mice, which in many respects manifest pathologic changes similar 
to those in human SLE. However, human SLE patients rarely have 
mutations of Fas or FasL, and thus these are not susceptibility genes in 
humans. Nevertheless, it is possible that some proteins (e.g., DcR3) 
indirectly interfering with the Fas/FasL pathway in humans might be lupus 
pathogenic. In support of this possibility, we have reported previously that 
activated T cells produce DcR3 (15). Of greater relevance, it has been 
demonstrated that PBMCs from SLE patients present higher levels of 
DcR3 transcripts than those from healthy individuals (17). We have 
observed augmented serum levels of DcR3 in a subpopulation of SLE 
patients during flares (Han B, et al: unpublished observations). Further, we 
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have demonstrated in this study that DcR3 overexpression resulted in a 
lupus-like syndrome in mice. 
In theory, the interference of DcR3 in the Fas apoptosis pathway might 
also be involved in the autoimmune lymphoproliferative syndrome (ALPS). 
Although Fas, FasL, caspase 8, or caspase 10 mutations have been found in 
66% of ALPS patients, the remaining 34% have no identifiable mutation 
(31). It would be interesting to investigate whether DcR3 overexpression 
occurs in this subpopulation. 
It should be noted that although DcR3 can potentially block at least 3 
apoptosis pathways, i.e., Fas/FasL, LIGHT/HVEM-LT R, and TL1A/DR3, 
SLE pathogenesis is most likely related to its interference with the 
Fas/FasL pathway. No SLE phenotype has been observed in LIGHT- or 
DR3-null mutant mice (32,33). 
We have previously shown that 60-70% of patients with various types of 
tumor have elevated serum levels of DcR3, as do patients with liver 
cirrhosis (16). However, these patients normally do not develop SLE as a 
complication. It is possible that local biologically active DcR3 in lymphoid 
organs has pathogenic potential for the development of SLE. Indeed, our in 
vitro experiments demonstrated that DcR3 secreted by spleen cells from 
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transgenic mice was sufficient to protect activated T cells against death 
(Figure 6). Furthermore, we conducted whole-body irradiation on 
wild-type mice, followed by bone marrow transplantation. Six months after 
transplantation, 5 of 8 recipients of DcR3-transgenic mouse bone marrow 
developed anti-dsDNA antibodies, a hallmark of SLE; moreover, these 
mice had renal and liver histopathologic features similar to those in 
DcR3-transgenic mice. Conversely, none of the 5 recipients of wild-type 
mouse bone marrow developed anti-dsDNA antibodies (data not shown). 
Taken together, these results indicate that abnormal overexpression of 
DcR3 by leukocytes is sufficient to cause an SLE-like syndrome, probably 
due to high local levels of biologically active DcR3 in lymphoid organs. 
It could be argued that the serum DcR3 levels of 20-80 ng/ml in our 
DcR3-transgenic mice, 2 orders of magnitude higher than levels seen in 
SLE patients, are not physiologically or pathologically relevant. In a report 
by Hsu et al describing transgenic mice with phosphoglycerate kinase 
(PGK) promoter-driven DcR3 expression, with serum DcR3 levels of 4.7 
ng/ml (34), an associated SLE-like phenotype was not mentioned. It is not 
clear whether transgenic mice with PGK promoter-driven DcR3 expression 
have been studied carefully beyond the age of 6 months. If these mice do 
not develop an SLE-like syndrome at an older age, it is possible that either 
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1) very high DcR3 levels are required for SLE pathogenesis and DcR3 is 
thus unlikely pathogenic in most patients, or 2) human DcR3 might not 
interact with mouse ligands with similar affinity as it would with human 
ligands. It is worth mentioning that although the binding affinity of human 
DcR3 to its human ligands has been demonstrated by us previously (6) and 
human DcR3 is known to interact with mouse FasL, LIGHT, and TL1A (9), 
the affinity of human DcR3 with mouse ligands has not been documented. 
Linkage analysis in lupus-prone mice has revealed 30 lupus 
susceptibility loci (1). However, such studies in mice cannot identify DcR3 
as an SLE susceptibility gene, because DcR3 is a human gene with no 
orthologous counterpart in mice. In a study of European and African 
Americans (35), an SLE locus was located at 20q13 (logarithm of odds 
2.49) near marker D20S481, which is situated 7.6 Mb from the DcR3 
gene. However, a more recent fine mapping study (36) placed an SLE risk 
locus at 20Q13.1, which is a considerable distance from the DcR3 gene (
20 Mb). Thus, further fine mapping genetic analyses in humans are 
warranted to establish whether DcR3 or its expression regulators are bona 
fide susceptibility genes that have a pathogenic role in SLE. 
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FIGURES AND LEGENDS 
Figure 1. Generation and characterization of decoy receptor 3 (DcR3)-transgenic mice. 
 
 
A, pAC-DcR3 construct for generation of transgenic mice. The 5.7-kb Cla I/Cla I 
fragment was used for microinjection. Amp R = ampicillin resistant. B, Polymerase 
chain reaction genotyping of tail DNA from DcR3 founder and wild-type (WT) mice. 
The 128-bp bands specific to the DcR3 transgene are indicated; pAC-DcR3 was used as 
a positive control. C, Serum DcR3 levels in 2-month-old DcR3-transgenic (Tg) and WT 
mice, determined by enzyme-linked immunosorbent assay (ELISA). D, DcR3 secreted 
in culture supernatants of spleen T cells from Tg or WT mice, determined by ELISA. 
Values are the mean and 2 SD from 2 independent experiments. 
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Figure 2. Lymphadenopathy and survival rates in DcR3-Tg mice. 
 
 
A, Lymphadenopathy in a 7-month-old female Tg mouse. B, Incidence of 
lymphadenopathy in 6-8-month-old male and female Tg mice. C, Enlargement of the 
spleen of a 9-month-old female Tg mouse with lymphadenopathy, compared with that 
of a WT mouse. D, CD4-,CD8- double-negative cells in enlarged lymph nodes of Tg 
mice. Cells from enlarged lymph nodes were analyzed by 3-color flow cytometry, and 
Thy1.2-positive T cells were gated and further analyzed by CD4 and CD8 staining. The 
experiments were performed 3 times; data from a representative experiment are shown. 
E, Further phenotype analysis of cells from enlarged lymph nodes of Tg mice. Cells 
were stained with B220 and Th1.2, and B220+,Th1.2+ cells were gated and further 
analyzed for expression of CD3, T cell receptor (TCR ), CD4, CD8, CD44, and 
CD62L. Shaded areas show data on cells gated on B220+,Thy1.2+; white areas show 
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data on isotype controls. The experiments were performed 3 times; data from a 
representative experiment are shown. F, Survival rates in WT, female Tg, and male Tg 
mice. See Figure 1 for other definitions. 
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Figure 3. Autoantibodies and B-1 cells in DcR3-Tg and WT mice. 
 
A, Presence of autoantibodies against various organs. Proteins from heart (H), liver (Li), 
lung (Lu), kidney (Ki), brain (Br), muscle (M), or submaxillary glands (Sbm) were 
blotted onto membranes after sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis and reacted with sera (1:500 dilution) from a Tg mouse (7-month-old 
female with lymphadenopathy) and a WT littermate (female). The experiments were 
performed 3 times, with similar results. B, Presence of antinuclear antibody. Sera 
(1:500 dilution) from a Tg mouse (7-month-old female with lymphadenopathy) and a 
WT littermate were reacted with permeabilized HeLa cells, followed by fluorescein 
isothiocyanate-conjugated goat anti-mouse IgG. The experiments were performed 3 
times, with similar results (original magnification × 400). C, Presence of 
anti-double-stranded DNA antibody (anti-dsDNA Ab). Levels of anti-dsDNA antibody 
in sera from >6-month-old female Tg mice, male Tg mice, and WT littermates were 
determined by ELISA. The mean plus 2 SD in WT mice was used as the threshold for 
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positivity. The frequency of positivity was significantly greater in female Tg mice and 
male Tg mice versus WT mice (P = 0.000353 and P = 0.00377, respectively, by 
chi-square test). OD = optical density. D, CD5+ B-1 cell population in peripheral blood 
mononuclear cells (PBMCs). CD19+ B cells from the peripheral blood of >6-month-old 
Tg and WT mice were gated and analyzed by 2-color flow cytometry for CD5 
expression. A large CD5+ B-1 cell population was found in Tg mice. The experiments 
were performed >3 times, with similar results. E, B-1a cell percentage in peritoneal B 
cells. Peritoneal cells from Tg and WT mice were gated on CD19 and analyzed by flow 
cytometry for CD5 and CD11b expression. Percentages of B-1b (CD5-,CD11b+) and 
B-1a (CD5+,CD11b+) populations among CD19+ cells are indicated; the percentage of 
B-1a cells was increased in Tg mice. The experiments were performed twice, with 
similar results.  
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Figure 4. Tissue histopathology and urine and hematologic findings in aged DcR-Tg 
and WT mice. 
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A, Renal histopathology. Kidney sections from 9-month-old female Tg and WT mice 
were stained with hematoxylin and eosin (HE), fluorescein isothiocyanate 
(FITC)-conjugated sheep anti-mouse IgG, or FITC-conjugated rat anti-mouse C3. B, 
Leukocyte, protein, and hemoglobin levels in urine. Urine from Tg and WT mice was 
collected for a 24-hour period, and leukocytes, protein, and hemoglobin were measured 
semiquantitatively with Chemstrip. Severity was graded -, +, ++, or +++ (- = negative; 
+++ = severe). Findings in female Tg mice were significantly different from those in 
WT mice for all 3 parameters (P < 0.05 by one-way analysis of variance with 
Kruskal-Wallis test), whereas findings in Tg males and WT mice were not significantly 
different. C, Liver histopathology. Liver sections from a 13-month-old female Tg 
mouse with lymphadenopathy and a female WT littermate were stained with 
hematoxylin and eosin. D, Skin histopathology. Skin lesions from a 14-month-old 
female Tg mouse (pure C57BL/6 background) with lymphadenopathy are shown in the 
upper panel. Hematoxylin and eosin staining of a skin section from this area is depicted 
in the lower panel. Lymphocyte-infiltrated derma and adjacent normal derma are 
indicated. E, Leukopenia, anemia, and thrombocytopenia. Levels of white blood cells, 
hemoglobin, and platelets in the peripheral blood of >6-month-old female Tg mice, 
male Tg mice, and WT littermates were determined. The mean minus 2 SD in WT mice 
was used as the threshold for abnormality. Findings in female Tg mice were 
significantly different from those in WT mice for all 3 parameters (P < 0.05 by 
chi-square test), whereas findings in Tg males and WT mice were not significantly 
different. (Original magnification × 200 in A; × 100 in C and D.) See Figure 1 for other 
definitions. 
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Figure 5. DcR3-induced protection of T cells against apoptosis. 
 
A, Protection against apoptosis in activated CD4 and CD8 cells. WT and Tg mouse 
spleen cells were first activated for 48 hours with soluble anti-CD3, then washed and 
recultured for 48 hours in the presence of interleukin-2, washed again, and transferred 
to wells coated with anti-CD3 for an additional 48-hour culture in the absence or 
presence of DcR3 at various concentrations. Apoptosis of CD4 and CD8 cells was 
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analyzed by annexin V staining on CD4- or CD8-gated cells in 3-color flow cytometry, 
after propidium iodide-positive cells were gated out. The experiments were performed 
at least twice, and data from a representative experiment are shown. B and C, DcR3 
blocking of FasL-induced apoptosis in resting T cells. WT and Tg mouse spleen cells 
were cultured for 16 hours in the absence or presence of crosslinked FasL, and 
apoptosis of CD4 and CD8 cells was analyzed by annexin V staining in 2-color flow 
cytometry. WT = WT mouse CD4 or CD8 cells without protection; DcR3-Fc = WT 
mouse CD4 or CD8 cells protected by 10 g/ml exogenous recombinant DcR3-Fc; Tg 
= DcR3-Tg mouse CD4 or CD8 cells protected by endogenous DcR3. The experiments 
were performed at least twice, with similar results. D, Dose-response of DcR3 
protection. WT mouse spleen cells were incubated with crosslinked FasL in the 
presence of DcR3 at various concentrations. Values are the mean ± SD. The 
experiments were performed twice, with similar results. See Figure 1 for other 
definitions. 
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Figure 6. Expanded CD44high,CD62Llow,CD25- CD4 population in peripheral blood 
mononuclear cells (PBMCs) of DcR3-Tg mice. 
 
CD4 cells in the peripheral blood of 6-month-old female Tg mice or WT littermates 
were gated, and expression of CD62L, CD44, and CD25 was analyzed. The 
experiments were performed >9 times, with similar results. A, Histograms from a 
representative set of experiments. B and C, Mean and SD percentages of 
CD44high,CD25- cells (B) and CD44high,CD62Llow cells (C) among total CD4 cells in 
the peripheral blood of female Tg, male Tg, and WT mice. = P < 0.01 versus WT 
mice, by Student's 2-tailed t-test. See Figure 1 for other definitions. 
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Article 2. 
DcR3 as a diagnostic parameter and risk factor for systemic 
lupus erythematosus 
Bing Han, Rafael Bojalil, Luis M. Amezcua-Guerra, Rashidi Springall, 
Héctor Valderrama-Carvajal, Jiangping Wu and Hongyu Luo 
 
Int Immunol. 20(8):1067-75, 2008. 
 
Summary: In this paper, we showed high serum DcR3 levels in SLE 
patients. We also demonstrated that hemopoietic cell secreted DcR3 was 
sufficient to induce lupus-like syndromes in mouse. Our results suggest 
that DcR3 is a risk factor for SLE, and this finding can lead to a new 
parameter for clinical diagnosis of SLE. 
 
Bing Han performed all assays and experiments, and processed and 
analyzed data; Rafael Bojalil, Luis M. Amezcua-Guerra, Rashidi Springall 
and Héctor Valderrama-Carvajal supplied sera and clinic data of SLE 
patients; Jiangping Wu and Hongyu Luo directed the experiment design 
and data analysis.
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ABSTRACT 
In this study, we investigated the diagnostic value of serum death decoy 
receptor 3 (DcR3) for systemic lupus erythematosus (SLE). The possible 
pathogenic role of DcR3 in SLE was also assessed. Serum DcR3 levels of 
90 SLE patients, 11 patients with rheumatic conditions and 123 healthy 
controls were determined by ELISA. In all, 43% of the SLE patients, 9% of 
patients with rheumatic conditions and 2.4% of the normal healthy 
individuals presented elevated serum DcR3 levels. A higher percentage of 
DcR3-positive SLE patients, compared with DcR3-negative SLE patients, 
showed abnormally high serum IgE levels, a surrogate marker of Th2-type 
immune responses. To determine the cause and effect relationship of DcR3 
expression and a Th2-prone status, we studied young DcR3 transgenic (Tg) 
mice, whose transgene was driven by an actin promoter. These mice had 
IL-4 overproduction and augmented serum IgE levels, signs of dominant 
Th2 immune responses. To determine possible SLE pathogenic roles of 
DcR3, the T-cell-depleted bone marrow of DcR3 Tg mice was transplanted 
into lethally irradiated syngeneic C57BL/6 female mice. The recipients 
developed an SLE-like syndrome. They presented anti-dsDNA and 
anti-nuclear antibodies, along with renal and liver pathology compatible 
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with that of SLE. In total, 90% of Tg bone marrow-transplanted mice, 
compared with 20% of wild-type bone marrow-transplanted mice, perished 
within 12 months after the transplantation. Our results showed that serum 
DcR3 could serve as an additional parameter for SLE diagnosis and that 
DcR3 secreted from cells of hematopoietic origin was SLE pathogenic in 
mice.  
Keywords: DcR3, systemic lupus erythematosus 
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INTRODUCTION 
Systemic lupus erythematosus (SLE) is an autoimmune disease inflicting 
damage to multiple organs. The disease prevalence is 0.05% in the 
general population, with 80–90% of patients being women (1, 2). The exact 
etiology of SLE has not been elucidated, but it is obvious that genetics, 
gender, and environment are involved in its pathogenesis. Regarding 
genetics, SLE is under polygenic control (3). Multiple genomic loci 
containing SLE risk genes have been identified in humans and mice (4, 5). 
Certain class II MHC genes are known to contribute to SLE risk (6). 
Among others, molecules in the apoptosis pathways are implicated in SLE 
pathogenesis (7). In mice, mutations in the prototype pro-apoptotic 
molecules Fas or Fas ligand (FasL) lead to the occurrence of an SLE-like 
syndrome (8, 9), but human SLE patients rarely have mutations in Fas or 
FasL (10, 11). However, it is possible that molecules in the Fas/FasL 
pathway are SLE risk factors, but they have yet to be identified as such.  
Decoy receptor 3 (DcR3) is a member of the tumor necrosis factor (TNF) 
receptor family. As it lacks transmembrane and intracellular sequences in 
its peptide, it is a secreted protein (12). It can bind to three TNF family 
members, i.e. FasL, LIGHT and TL1A, and interferes with the interaction 
of these ligands with their respective receptors, i.e. FasL with Fas, LIGHT 
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with HVEM and LTβR and TL1A with DR3 (12–15). Because these 
receptors are all capable of inducing cell death (15–17), one of DcR3's 
biological functions is to act as a death decoy, preventing cell death under 
certain circumstances (15). In total, 50–60% of various tumors secrete 
DcR3 (18), which is probably a strategy evolved by tumors to gain a 
survival advantage over immune surveillance. Activated T cells also 
produce DcR3 (19). The biological significance of such DcR3 production 
could be (i) to modulate activation-induced cell death after clonal 
expansion and, hence, influence memory T-cell development (20) and (ii) 
to regulate T-cell migration after their activation as we have found that 
soluble DcR3 can inhibit T-cell chemotaxis (21).  
T cells in SLE patients are abnormally activated. As activated T cells 
produce DcR3 (19), we examined serum DcR3 in these patients as a 
possible diagnostic marker. We further investigated a possible role of 
DcR3 in SLE pathogenesis.  
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METHODS 
Patients and healthy controls 
Sera from SLE patients, patients with other autoimmune diseases and 
healthy controls were collected at the Department of Immunology, Instituto 
Nacional de Cardiología ‘Ignacio Chávez’, Mexico City. Informed consent 
was obtained from serum donors, and this study was approved by the local 
Ethic Committee. All SLE patients (86 females and 4 males; age between 
16 and 63, 37.3 ± 12.9) met the American College of Rheumatology 
classification criteria (22). The systemic lupus erythematosus disease 
activity index (SLEDAI) of each patient was obtained at the time of serum 
collection. All the patients were under one to four different medications, 
which were duly recorded and illustrated in relevant figures. Eleven 
patients (nine females and two males) between 20 and 59 years of age 
(38.8 ± 13.5) with rheumatic conditions [three with rheumatoid arthritis, 
one with idiopathic juvenile arthritis, one with anti-phospholipid syndrome, 
two with Sjögren syndrome, one with thrombophilia, two with 
undifferentiated connective tissue disease, one with overlap syndrome 
(systemic sclerosis plus polymyositis)] were included for comparison. 
Control sera were from healthy donors (92 females and 31 males; age 
between 18 and 64, 35.6 ± 10.5) approximately matched for age and gender 
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of SLE patients. All the patients and healthy controls were Mexican 
Mestizo.  
DcR3 ELISA 
DcR3 ELISA has been described elsewhere (18). An mAb specific to 
DcR3 was used for coating, and a biotinylated affinity-purified rabbit 
antibody against DcR3 served as detecting antibody. The sensitivity of the 
assay was 6 pg ml–1. Human samples were tested in duplicate, and mouse 
samples, in triplicate. The mean + 1.64 SD (95% confidence interval, 
one-sided test) of the control serum DcR3 levels was used as the threshold 
(25 pg ml–1), levels equal or above which were considered DcR3 positive.  
Clinical serological tests 
Serum anti-nuclear antibodies (ANAs) were detected by indirect 
immunofluorescence on HEp-2 cells slides (NOVA Lite, INOVA 
Diagnostics, San Diego, CA, USA). Anti-dsDNA antibodies were detected 
by indirect immunofluorescence on Crithidia luciliae substrate (NOVA Lite, 
INOVA Diagnostics). Anti-SSA, anti-SSB, anti-RNP and anti-SM 
antibodies were all detected by ELISA (QUANTA Lite, INOVA 
Diagnostics). All the assays were performed according to manufacturer's 
instructions.  
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Human serum IgE assay 
Human serum IgE was quantified using an ELISA kit from Bethyl 
Laboratories (Montgomery, TX, USA), according to the manufacturer's 
instructions. The sensitivity of the assay was 16 ng ml–1.  
Cell culture 
Mouse spleen cells were cultured in 96-well plates at a density of 4 x 105 
cells per 200 µl per well and stimulated with phorbol myristate acetate 
(PMA, 10 nM) and ionomycin (2 µg ml–1) for 4 h in the presence of 
brefeldin A (10 µg ml–1) for the detection of intracellular IL-4 and IFN- .  
Flow cytometry 
Two-color flow cytometry was performed to determine the expression of 
CD4 and intracellular IL-4 and IFN-  in mouse spleen T cells, as 
described before (23).  
Measurement of Ig isotype levels in mouse sera 
Mouse serum Ig isotype levels were quantified with Ig-isotyping ELISA 
and OptEIA kits from BD Biosciences (Mississauga, Ontario, Canada), 
according to the manufacturer's instructions.  
Whole-body irradiation and bone marrow transplantation 
C57BL/6 female mice were whole-body irradiated at 900 Rad. After 16 h, 
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they received intravenously (i.v.) 10 million T-cell-depleted bone marrow 
cells from DcR3 or wild-type (WT) mice. T-cell depletion from bone 
marrow cells was carried out with EasySep Mouse CD90 (Thy1.2) Positive 
Selection Kit according to the manufacturer's instructions (StemCell 
Technologies Inc., Vancouver, BC).  
Immunofluorescence for the detection of ANA 
HeLa cells were fixed with a BD Cytofix/Cytoperm kit (BD Biosciences, 
San Diego, CA, USA) at 4°C for 60 min and then incubated overnight at 
4°C with sera from mice having received WT bone marrow transplantation 
(BMTx) or transgenic (Tg) BMTx (1:500 dilution in wash buffer from the 
kit). After washing, the cells were reacted overnight at 4°C with 
FITC-conjugated goat anti-mouse IgG antibody (1:1000 dilution; Bethyl 
Laboratories). The cells were examined under fluorescence microscopy. 
The method was similar to that as described by Vinuesa et al. (24).  
ELISA for anti-dsDNA 
Costar 96-well high-affinity ELISA microplates were coated with 250 µg 
ml–1 salmon sperm DNA (Invitrogen, Burlington, Ontario, Canada) in 
coating buffer (0.05 M sodium bicarbonate solution, pH 9.5) overnight at 
4°C. After washing with PBS containing 0.05% Tween 20, the plates were 
incubated with blocking buffer (PBS containing 1% BSA) at room 
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temperature for 1 h. WT and Tg mouse sera were diluted in blocking buffer 
at 1:50 and incubated overnight in the wells at 4°C. After washing, the 
plates were reacted with HRP-conjugated sheep anti-mouse IgG antibody 
(1:2000 dilution; Amersham Biosciences, Piscataway, NJ, USA) for 1 h at 
room temperature. Signals were revealed by adding tetramethylbenzidine 
substrate (BD Biosciences), followed by 20-min incubation at room 
temperature. The reaction was stopped by 50 µl 4 N HCl, and the plates 
were read at a wavelength of 450 nm.  
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RESULTS 
Elevated serum DcR3 levels in SLE patients 
Sera from 90 SLE patients (86 females and 4 males) and 123 
approximately age- and gender-matched healthy individuals (92 females 
and 31 males) were tested for DcR3. As shown in Fig. 1(A), SLE patients 
presented elevated serum DcR3, with 39 of them (i.e. 43.3% of total 
patients; 75% of males and 41.9% of females) being serum DcR3 positive, 
compared with only 3 out of the 123 healthy controls (2.4%). The 
difference was highly statistically significant (P < 0.01, Student's t-test). In 
these patients, who were all under medication, DcR3 levels had no obvious 
correlation with SLEDAI, according to linear regression analysis (r = 0.119, 
P = 0.26) (Fig. 1B). No significant correlation was found between age 
(ranging from 16 to 64 years) and serum DcR3 levels (r = –0.1, P = 0.92; 
Fig. 1C). Further analysis showed that serum DcR3 positiveness was not 
correlated to positiveness of ANA, anti-dsDNA antibody, anti-RNP 
antibody, anti-Sm antibody, anti-Ro/SSA antibody or anti-La/SSB antibody 
(P > 0.05, 2 test; Fig. 1D). 
For comparison, DcR3 levels in 11 patients with rheumatic conditions were 
determined. Only 1 out of 12 (9%) of these patients were positive in serum 
DcR3. The DcR3-positive patient in this group was diagnosed with overlap 
syndrome (systemic sclerosis plus polymyositis). Although a large sample 
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size of each disease will be needed to assess the DcR3-positive incidence, 
our data at least suggest that DcR3-positive incidence in rheumatic 
conditions is not as high as that in SLE.  
All SLE patients were under medication, such as cyclophosphomide 
(CFM), prednisone (PDN), hydroxychloroquine (HCQ), azathioprine (AZA) 
and/or statins, at the time of serum collection. Only 13 patients were on a 
single medication (11 on HCQ and 2 on PDN); all the others were treated 
with two to four drugs. We attempted to determine whether any particular 
drug would influence serum DcR3 and whether, in the absence of the said 
drug, there was a correlation between SLEDAI and DcR3 levels. Patients 
without a particular medication but on one to three other medications were 
compared with those taking the said medication along with zero to three 
other drugs. As shown in Fig. 2(A), regimens containing CFM, PDN and 
AZA did not seem to affect serum DcR3 levels. On the other hand, patients 
on regimens without HCQ appeared to have higher DcR3 levels. This was 
probably due to that patients taking HCQ were those with a lower SLE 
activity. Indeed, SLEDAI of patients with a regimen containing HCQ 
tended to be lower than that without HCQ (Fig. 2B), although the 
difference did not reach a statistically significant level. We also noticed that 
patients on a regimen containing statins presented higher DcR3 levels (Fig. 
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2A; P < 0.004), and they also had higher SLEDAI (Fig. 2B), albeit without 
reaching statistically significance. Possible explanations for such an 
observation are given in the Discussion. Another observation was that 
patients treated with a regimen containing PDN or AZA had significantly 
higher SLEDAI (P = 0.03 in both cases). This is not unexpected as these 
two drugs are normally administered to patients with elevated SLEDAI.  
Elevated serum IgE levels in SLE patients 
SLE is an autoimmune disease with an underlying Th2 immune response, 
and physiological conditions such as pregnancy that boosts the Th2 
response tend to aggravate SLE (25). We wondered whether there was any 
correlation between serum DcR3 levels and the degree of Th2 dominance. 
To test this possibility, serum IgE was employed as a surrogate marker of 
Th2 response. The 90 SLE patients were divided into DcR3-positive and 
DcR3-negative groups, with 25 pg ml–1 serum DcR3 as the threshold. The 
results (Fig. 3) showed that DcR3-positive patients had an elevated serum 
IgE concentrations (with a median IgE concentration of 120 ng ml–1) 
compared with DcR3-negative patients (with a median IgE concentration 
of 60 ng ml–1). A higher percentage of DcR3-positive patients presented 
serum IgE levels above the normal range using 240 ng ml–1 (100 IU ml–1) 
as the upper limit of the range (26), compared with DcR3-negative patients 
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(P < 0.05; 2 test). These results suggest the existence of a correlation 
between DcR3 levels and the Th2 phenotype. 
Th2-prone immune responses in young DcR3 Tg mice 
To establish the cause and effect relationship between DcR3 expression and 
Th2-prone immune responses, we generated actin promoter-driven human 
DcR3 Tg mice (20). The mouse does not have an orthologue of human 
DcR3, but human DcR3 could effectively interact with mouse FasL, 
LIGHT and TL1A (12, 27). Tg mice younger than 5–6 months of age, 
thymus, spleen and lymph node weight and cellularity were in the normal 
range, as were cell sub-populations in these organs (data not shown). Their 
T-cell proliferation in response to solid-phase anti-CD3 alone or in 
combination with anti-CD28 was variable and did not have consistent 
changes in comparison to WT T cells [data not shown; methods detailed in 
Luo et al. (23)]. However, when Tg CD4 cells experienced a short-term 
ionomycin and PMA stimulation, a higher percentage of them became 
intracellular IL-4- but not IFN- -positive, compared with WT CD4 cells 
(Fig. 4A). Because such a stimulation regimen triggered previously 
activated rather than resting T cells to secrete these lymphokines, this result 
suggests that Tg mice at this age already experienced a Th2-dominated 
immune response history. 
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The serum antibody isotypes of these Tg mice were determined by ELISA. 
As illustrated in Fig. 4(B), Tg and WT mice had similar levels of IgA, IgM, 
IgG2A and IgG3, but Tg mice produced higher amounts of IgG1 and 
IgG2b than WT mice. Tg mice also generated increasingly significantly 
higher concentrations of IgE, a typical Th2-dependent isotype, from 2 to 6 
months of age (Fig. 4C). The overproduction of IgG1 and IgE indicated 
that the immune responses in Tg mice were skewed to the Th2-type 
response and was consistent with increased intracellular IL-4-positive CD4 
cells found in the spleens of young Tg mice. These results suggest that 
DcR3 over-expression is a cause of Th2-prone immune responses.  
Recipients of DcR3 Tg bone marrow developed an SLE-like syndrome 
Tg mice with actin promoter-driven DcR3 expression developed an 
SLE-like syndrome after 5 months of age (20). They produced 
auto-antibodies against dsDNA and Smith antigen. The kidneys of these Tg 
mice showed pathological changes indicative of glomerular nephritis and 
IgG and C3 deposition; kidney dysfunction, such as proteuria, leukocyturia, 
and hemuresis, were obvious. Aged Tg mice also developed skin lesions 
and lymphocyte infiltration in the liver and suffered from leukopenia, 
anemia and thrombocytopenia. SLE-like syndrome penetrance in DcR3 Tg 
mice was gender dependent, with 60% in females versus 20% in males. 
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These findings have been reported by us recently (20). The results suggest 
that DcR3 might be SLE pathogenic. In actin promoter-driven DcR3 Tg 
mice, DcR3 was produced almost universally by various tissues. Because 
activated T cells secrete DcR3 (19), we wondered whether DcR3 from such 
a source was sufficient to cause SLE. To explore this possibility, we 
irradiated C57BL/6 female mice at a lethal dosage (900 Rad) and 
transplanted i.v. T-cell-depleted bone marrow cells from DcR3 Tg mice. 
For controls, C57BL/6 female mice underwent whole-body irradiation 
(WBI), followed by BMTx from WT mice. Sera of Tg BMTx but not WT 
BMTx recipients contained human DcR3 as shown in Fig. 5A. Four 
months after transplantation, five of the eight Tg BMTx recipients 
developed anti-dsDNA antibody, a hallmark of SLE, according to ELISA, 
while none of the five controls receiving WT BMTx had such antibody 
(Fig. 5B). However, there was no correlation between the levels of DcR3 
and anti-dsDNA antibody (Fig. 5C). Those Tg BMTx recipients also 
produced ANA (Fig. 5D), another typical laboratory finding in SLE.  
Human SLE is associated with glomerulonephritis. Renal pathology was 
thus assessed in mice 6 months after Tg BMTx, according to 
hematoxylin–eosin staining (Fig. 5E, top panel). The kidneys showed mild 
interstitial congestion and edema, with moderate interstitial cell infiltration, 
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particularly around the blood vessels. Some glomeruli were extended in 
size, and capillary loops were markedly thickened and obliterated. 
Epithelial cells of Bowmen's capsule proliferated focally. These 
pathological findings were compatible with glomerulonephritis.  
In the liver of mice 6 months after Tg BMTx, periarterial lymphocyte 
infiltration (Fig. 5E, lower panel) was similar to the liver pathology seen in 
SLE patients (28).  
The survival rate of WBI–BMTx mice is shown in Fig. 6. Twelve months 
after WBI–BMTx, 80% WT bone marrow recipients were still alive, but 
only 10% DcR3 Tg bone marrow recipients survived after this period. This 
finding was similar to that in DcR3 Tg female mice without WBI–BMTx 
(20).  
These findings establish that DcR3 over-expression by cells of 
hematopoietic origin suffices to induce the SLE-like syndrome. 
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DISCUSSION 
In this study, we demonstrated that SLE patients had elevated serum DcR3 
levels, compared with healthy individuals. We further proved that DcR3 
over-expressed by cells of hematopoietic origin was sufficient to induce the 
SLE-like syndrome in mice.  
SLE has complex clinical manifestations, and additional laboratory 
parameters are certainly needed for more accurate diagnosis. As 43.3% of 
the SLE patients but only 2.4% healthy controls in our cohort were DcR3 
positive, serum DcR3 could be employed as a new parameter in addition to 
the current ones for SLE differential diagnosis. It should be mentioned that 
9% patients with rheumatic conditions (this study), 60% of tumor patients 
and some liver cirrhosis patients are serum DcR3 positive (18), and these 
conditions should be taken into consideration if DcR3 is employed for SLE 
differential diagnosis.  
All the patients in our cohort were treated with one to four medications. 
The fact that elevated serum DcR3 was detected in these patients suggests 
that serum DcR3 positiveness can be used for SLE diagnosis, even if they 
are treated with symptom-relieving medications before a final diagnosis of 
SLE is made.  
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No correlation between SLEDAI and quantitative DcR3 levels was found 
in our SLE cohort, but it is quite possible that the medications might 
suppress DcR3 production and abolish possible correlations. A prospective 
study on the relationship between DcR3 levels and SLEDAI in patients 
without medication is underway to address this question. Still, by analyzing 
the current data, we attempted to extract some information on the 
relationship between DcR3 levels and SLEDAI. We note in Fig. 2(A) that 
the 15 patients on a drug regimen containing no HCQ presented higher 
DcR3 levels. A careful look at these patients revealed that 12 of the 15 
were on a regimen containing CFM and/or AZA, an indication of more 
severe disease activity, while 11 of the 75 patients on a regimen containing 
HCQ were under single-drug therapy, an indication of milder disease 
activity only involving skin lesions. Indeed, patients receiving a regimen 
containing no HCQ showed a higher SLEDAI than that with HCQ, 
although the difference was not statistically significant (Fig. 2B). This 
raises the possibility that the reduced DcR3 levels in patients treated with 
HCQ are not a consequence of drug administration but are due to lower 
disease severity in this sub-population to start with.  
Statins are used to lower blood cholesterol to control cardiovascular 
complications in SLE (29). Patients treated with a regimen containing 
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statins had statistically significantly higher DcR3 levels (Fig. 2A); their 
SLEDAI was also higher than those on a regimen without statins, although 
the difference was not statistically significant (Fig. 2B). In our SLE cohort, 
statins were not particularly used for a selected group of patients with a 
severer or less severe form of disease. Statins, particularly 
second-generation statins, such as simvastatin and atorvastatin, have 
unexpected immunoregulatory functions, in addition to its 
cholesterol-lowering effect (30). An increasing number of cases with 
statin-induced lupus-like syndrome have been reported (31, 32). Taking 
such literature and our findings as a whole, an intriguing possibility is that 
statins increase DcR3 levels and aggravate SLE disease activity. Additional 
perspective studies including non-SLE patients taking statins will be 
necessary to verify this possibility.  
While this article DcR3 was under review, Lee et al. (33) reported that 
serum DcR3 levels in oriental SLE patients were elevated, compared with 
healthy controls. The finding corroborated our report using a different 
ethnic population. In Lee's article, serum DcR3 levels were found to be 
positively correlated to SLEDAI. However, medication was not described 
in their patient cohort, and it will be necessary to confirm whether such 
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correlation only occurs in the absence of anti-inflammatory drugs or 
immunosuppressants.  
Aberrant apoptosis has been cited as a possible cause of SLE. Several 
genes involved in apoptosis are considered SLE risk factors. Mice with 
mutations in Fas and FasL, which are in the prototype apoptosis pathway, 
manifest an SLE-like syndrome. Human SLE patients rarely have Fas or 
FasL mutations, but DcR3 could be a culprit blocking the Fas apoptosis 
pathway and induce SLE. Because of DcR3 elevation in SLE patients, its 
known roles in blocking apoptosis and the putative relationship between 
disease severity and DcR3 levels in HCQ- and statin-treated patients, we 
studied DcR3 Tg mice to assess DcR3's role in the pathogenesis of SLE. In 
our Tg mice, DcR3 expression was driven by an actin promoter. To avoid 
complications due to universal DcR3 expression from cells other than those 
of hematopoietic origin, we transplanted T-cell-depleted Tg bone marrow 
into irradiated syngeneic recipients. These mice developed an SLE-like 
syndrome in 4 months after BMTx. They had anti-dsDNA and ANA and 
presented renal and liver pathology compatible with SLE. Thus, we proved 
that DcR3 secreted from cells of hematopoietic origin was SLE pathogenic 
in an animal model.  
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Why do a large percentage of tumor patients ( 60%) have DcR3 levels 
comparable to those of SLE patients (18) in the range of 30–200 pg ml–1, 
but they rarely develop SLE? It seems that serum DcR3, at least at 
concentrations present in tumor patients, is not SLE pathogenic. In mice 
receiving WBI followed by Tg BMTx, the serum DcR3 levels were much 
higher at a range of 2–80 ng ml–1. The biologically active local DcR3 
concentrations in lymphoid organs in both patients and Tg BMTx are 
probably much higher than their serum levels, and the presence of such 
high local DcR3 concentrations is a more likely culprit.  
As not all SLE patients are DcR3 positive, DcR3 is obviously only 
pathogenic or facilitates SLE development in a sub-population of SLE 
patients. The final proof of DcR3 in SLE pathogenesis will need to come 
from human genetic studies examining single-nucleotide polymorphisms in 
the DcR3 gene or genes regulating its expression in DcR3-positive SLE 
patients versus DcR3-negative healthy controls.  
It is interesting that, in lpr/lpr and gld/gld mice (with Fas and FasL 
mutations, respectively) and in our actin promoter-driven DcR3 Tg mice, a 
large percentage (>65% of females and 20% of males) develops 
lymphadenopathy along with their SLE-like syndrome (20). On the other 
hand, none of the WBI–BMTx female mice manifested lymphadenopathy, 
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in spite of their SLE-like syndrome. Similar to that in our WBI–BMTx 
mice, SLE patients rarely develop lymphadenopathy. It appears that our 
WBI–BMTx model more closely resembles human SLE, compared with 
lpr/lpr, gld/gld and DcR3 Tg mice. All the latter three SLE mouse models, 
in contrast to the WBI–BMTx mice, have one thing in common, i.e. 
compromised Fas-mediated apoptosis in non-hematopoietic cells. This 
raises an intriguing possibility that the development of lymphadenopathy 
needs interaction between T cells and Fas pathway-defective cells of 
non-hematopoietic origin.  
Our study has demonstrated that serum DcR3 can be considered as an 
additional SLE diagnostic parameter. Further genetic study in humans is 
needed to confirm its role in SLE pathogenesis as mice have no genes 
orthologous to human DcR3.  
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FIGURES AND LENGENDS 
Figure 1. Serum DcR3 levels and their relationship with SLEDAI in SLE patients. 
 
Serum DcR3 was assayed by ELISA in duplicate. DcR3 levels of 90 SLE patients (86 
females and 4 males), 11 patients with rheumatic conditions (two males and nine 
females) and 123 healthy controls (92 females and 31 males) were measured. The 
threshold of DcR3 positiveness (25 pg ml–1) was the mean + 1.64 SD of control serum 
levels. (A) SLE patients had elevated serum DcR3 levels. The serum DcR3 levels of 
SLE patients, patients with rheumatic conditions and healthy controls were 32 ± 32, 
22.7 ± 35.9 and 5 ± 12 pg ml–1, respectively (means ± SD). The difference between 
SLE patients and healthy controls and patients with rheumatic conditions and healthy 
controls were highly significant (P < 0.01 for both comparisons; Student's t-test), 
although the difference between SLE and rheumatic patients were not (P > 0.05, 
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Student's t-test). (B) SLE patient serum DcR3 levels plotted against SLEDAI. Serum 
DcR3 levels of 90 SLE patients are plotted against their SLEDAI (ranging from 0 to 
24). No correlation is found between these two parameters (r = 0.119, P = 0.26; 
Pearson correlation test). (C) SLE patient serum DcR3 levels plotted against their age. 
Serum DcR3 levels of 90 SLE patients are plotted against their age (16–64 years). No 
correlation is found between these two parameters (r = –0.100, P = 0.92; Pearson 
correlation test). (D) No correlation between positiveness of DcR3 and auto-antibodies 
in SLE patients. Serum DcR3 of SLE patients was determined as positive or negative 
using 25 pg ml–1 as a threshold (36 patients were DcR3 positive and 52 patients were 
DcR3 negative) and analyzed against positiveness of their serum ANA, anti-dsDNA, 
anti-RNP antibody, anti-Sm antibody, anti-Ro/SSA antibody and anti-La/SSB antibody, 
using 2 test. P-values were >0.05 in all the comparisons. The serum DcR3 
positiveness was marked as ‘+’ or ‘–’ under each comparison. Solid black and slashes 
indicate serum positiveness and negativeness of a certain auto-antibody, respectively. 
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Figure 2. Relationship among medication, serum DcR3 levels and SLEDAI of SLE 
patients. 
 
 
 
All 90 SLE patients were under medication, and 77 of them were under two to four 
drug treatments. Serum DcR3 levels of patients without a particular drug but with one 
to four other medications were compared with those taking that particular drug along 
with zero to three other medications. Patient number in each group and P-value 
(Student's t-test) are shown. (A) Serum DcR3 levels of SLE patients treated with a 
regimen containing or not containing a certain drug. SLE patients treated with a drug 
regimen containing HCQ or statins had higher serum DcR3 levels (P = 0.007 and P = 
0.004, respectively; Student's t-test). (B) SLEDAI of SLE patients treated with a 
regimen containing or not containing a certain drug. SLE patients treated with a drug 
regimen containing PDN or statins had higher SLEDAI (P = 0.03 in both cases; 
Student's t-test). 
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Figure 3. Elevated serum IgE levels in SLE patients. 
 
 
The serum IgE of 90 SLE patients were determined by ELISA, for which sera were 
tested in duplicate. The median IgE level in DcR3-negative patients was 60 ng ml–1 
(short horizontal bar) and that in DcR3-positive patients was 120 ng ml–1 (short 
horizontal bar). Using 240 ng ml–1 serum IgE concentration {the upper limit of normal 
serum IgE levels of healthy individuals [Bueno et al. (26)]} as a threshold, a 
significantly higher percentage of DcR3-positive SLE patients presented elevated 
serum IgE levels (41.0%), compared with that of DcR3-negative SLE patients (19.6%; 
P < 0.05, 2 test).  
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Figure 4. Th2-prone immune responses in young DcR3 Tg mice. 
 
The experiments were conducted in 2- to 4-month-old DcR3 Tg and WT littermates. (A) 
Increased intracellular IL-4 but not IFN-  in Tg CD4 cells. Spleen cells were either not 
stimulated (resting) or stimulated with PMA (10 nM) and ionomycin (2 µg ml–1) for 4 h. 
Intracellular IL-4 and IFN-  were analyzed by two-color flow cytometry (CD4/IL-4 or 
CD4/IFN- ). The experiments were repeated two times and data from a representative 
experiment are shown. (B) Serum IgM, IgA and IgG levels in 4-month-old Tg and WT 
littermates. Sera from DcR3 Tg and WT littermates (n = 5 pairs) were assayed by 
ELISA. Asterisks over IgG1 and IgG2b indicate statistically significant differences (P 
< 0.05, two-tailed Student's t-test). (C) Increased serum IgE levels in Tg mice. Serum 
IgE levels of DcR3 Tg and WT littermates at ages of 2, 4 and 6 months were assayed 
with ELISA. Median levels are indicated by horizontal bars. Each dot or triangle 
represents an individual mouse. Tg mice at all age groups present higher IgE levels than 
their littermates (P < 0.05, two-tailed Student's t-test).  
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Figure 5. Development of an SLE-like syndrome in WBI–BMTx mice. 
 
 
 
WBI female C57BL/6 mice received T-cell-depleted BMTx from DcR3 Tg or WT mice. 
Four months after BMTx, their serum DcR3, anti-dsDNA antibody and ANA were 
assessed. Tg BMTx, recipients of Tg BMTx; WT BMTx, recipients of WT BMTx. (A) 
Serum DcR3 levels of WBI–BMTx mice. Serum DcR3 levels of Tg BMTx or WT 
BMTx recipients 6 months after BMTx are shown. The latter had no detectable DcR3. 
(B) Anti-dsDNA antibody in Tg BMTx recipient sera according to ELISA. Sera from 
Tg BMTx or WT BMTx recipients were measured for anti-dsDNA 6 months after 
WBI–BMTx. The positive threshold was determined according to the mean + 2 SD of 
serum DcR3 levels of WT BMTx recipients. The DcR3 level difference between Tg 
BMTx and WT BMTx recipients is highly significant (P < 0.01, Student's t-test). (C) 
No correlation between serum DcR3 and anti-dsDNA levels in Tg BMTx recipients. 
For Tg BMTx recipients, their serum DcR3 levels were plotted against anti-dsDNA 
levels. No obvious correlation was observed. (D) ANA in Tg BMTx recipient sera 
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according to immunofluorescence. Sera from Tg and WT BMTx recipients 6 months 
after WBI–BMTx were reacted against permeabilized HeLa cells, and the cells were 
examined by immunofluorescence microscopy. (E) Kidney and liver pathology of Tg 
BMTx recipients. Hematoxylin–eosin staining of kidney and liver sections from 
6-month-old Tg BMTx recipients. Original magnification: x100. 
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Figure 6. Reduced survival rate in Tg BMTx recipients. 
 
 
WBI female C57BL/6 mice received Tg or WT BMTx. The survival rate of these 
recipients within 12 months after BMTx is plotted. The difference between these two 
groups is highly significant (P < 0.01; Student's t-test). 
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Article 3. 
DcR3 protects islet β-cells from apoptosis through modulating 
Adcyap1and Bank1 expression 
Bing Han and Jiangping Wu 
 
Under revision after submission to J. Immunol. 
 
Summary: In this paper, we investigated the mechanism of DcR3 in 
protecting islets. We found that: 1) the TL1A/DR3 pathway and the 
LIGHT/HVEM-LTβR pathway mediated islet apoptosis; 2) DcR3 transgenic 
islets were resistant to apoptosis; 3) two novel downstream mediators of 
DcR3’s effect, Adcyap1 and Bank1, were discovered. 
 
 
 
Bing Han performed all assays and experiments, and processed and analyzed 
data; Jiangping Wu directed the experiment design and data analysis.
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ABSTRACT 
 
The islet primary non-function (PNF) is a serious problem in islet 
transplantation. In this study, we investigated whether DcR3-secreting 
transgenic (Tg) islets could reduce PNF. We generated transgenic mice 
expressing human DcR3. The transgenically expressed DcR3 protected islets 
from IFN-γ plus IL-1β, or TNF-α plus IL-1β-induced dysfunction and 
apoptosis in vitro. The Tg islets presented significantly reduced PNF after 
transplantation. Mechanistically, in addition to the known FasL apoptotic 
pathway, components of two other apoptosis pathways, i.e., HVEM/LTβR 
for the LIGHT pathway, and DR3 for the TL1A pathway, were found to be 
expressed in islets. Recombinant LIGHT and TL1A induced islet apoptosis 
in the absence of the FasL/Fas pathway, and DcR3 could block such 
induction. These results for the first time demonstrated that, LIGHT and 
TL1A were capable of inducing islet apoptosis in addition to FasL, while 
DcR3 protected the islets by blocking all the three apoptosis pathways. By 
DNA microarray analysis, we discovered that Adcyap was upregulated more 
than 700 folds and Bank1 was downregulated 50 folds in the 
cytokine-assaulted Tg islets, compared to WT islets. Forced overexpression 
of Adcyap1 by plasmid transfection or knockdown of Bank1 expression by 
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siRNA in insulinoma NIT-1 cells protected them from cytokine-triggered 
apoptosis, indicating that indeed DcR3 protects β-cells via the action of 
these two downstream molecules. This study has revealed novel mechanisms 
by which DcR3 protects islet survival, and identified new therapeutic targets 
of diabetes. 
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INTRODUCTION 
 
Islet transplantation is an effective treatment for diabetes. Islet primary 
non-function (PNF) is a condition defined as the loss of islet function after 
transplantation for reasons other than graft rejection. It is one of the major 
obstacles limiting islet transplantation efficacy. PNF frequency can be very 
high in islet transplant models (1). In humans, pancreas transplantation 
produces better results than islet transplantation in reversing diabetic status 
(2), suggesting the occurrence of serious PNF in islet transplantation. With 
the best islet transplantation protocol, the Edmonton Protocol (3),  8 x 105 
islets on average (from two or more donors) are needed to achieve insulin 
independence (3, 4), and it is known that 3 x 105 islets in the pancreas are 
sufficient for insulin independence (5). This suggests that PNF is still a 
serious problem. 
 
Isolated islets experience dramatic stress from enzyme digestion, mechanical 
shear, and deprivation of obligatory trophic support (6,7,8). When these 
islets are transplanted into diabetic patients, they immediately face 
unfavorable conditions, such as inflammatory cytokines either released by 
local inflammatory responses or due to underlying diabetic conditions. 
These in vitro and in vivo factors result in islet dysfunction and apoptosis, 
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and consequently PNF. PNF is thus likely one of the major culprits in low 
islet transplantation efficiency. If PNF can be overcome, the efficacy of islet 
transplantation can be significantly increased. This would be equivalent to 
augmenting the donor supply. 
 
Human DcR3 belongs to the TNFR family (9), but lacks transmembrane and 
cytoplasmic domains in its sequence. It is thus a secreted protein (10). DcR3 
can bind to TNF family members FasL (9), LIGHT (10,11) and TL1A (12), 
and block their interaction with their respective receptors, i.e., Fas, HVEM 
and DR3 (10,11,12). The mouse does not have an orthologous counterpart of 
human DcR3 gene according to a genome-wide computer search.  We and 
others have established that human DcR3 can bind to mouse FasL, LIGHT 
and TL1A (9,10,12,13,14), allowing human DcR3 to function in mouse 
models both in vitro and in vivo. 
 
The role of DcR3 in apoptosis is obvious. FasL is a well-known molecule 
involved in apoptosis. LIGHT is a ligand for HVEM and LTβR, in addition 
to being a ligand for DcR3 (13). LIGHT can induce apoptosis in cells 
expressing both HVEM and LTβR15, or LTβR alone (14,15). TL1A, a 
member of the TNF family, can evoke apoptosis via its receptor DR3 (12). 
Consequently, the interaction of DcR3 with FasL, LIGHT, and TL1A blocks 
FACULTÉ  DES  ÉTUDES  SUPÉRIEURES  UNIVERSITÉ  DE  MONTRÉAL        BING HAN 151
apoptosis mediated by Fas, HVEM, LTβR and DR3. 
 
In this study, we generated transgenic (Tg) mice with actin promoter-driven 
human DcR3 expression. The minute amount of DcR3 secreted by these Tg 
islets rendered protection against PNF in vivo. We also discovered that 
LIGHT and TL1A mediated cytokine-triggered islet apoptosis. Through 
DNA microarray, we identified Adcyap1 and Bank1 as two critical 
downstream molecules mediating DcR3’s protective effect on islets. The 
essential roles of Adcyap1 and Bank1 in the case was confirmed by the fact 
that modulating their expression could indeed reduce β-cell apoptosis.  
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MATERIALS AND METHODS 
 
DcR3 ELISA 
DcR3 ELISA has been described elsewhere (16). A mAb and a biotinylated 
affinity-purified rabbit Ab specific to DcR3 were used for coating and 
detection, respectively. The sensitivity of the assay was 6 pg/ml.  
 
Islet isolation 
The islet isolation procedure has been detailed in our earlier publication 
(17). 
 
Flow cytometry 
Flow cytometry was performed to quantify the apoptosis of islet cells. The 
islets were first dispersed by trypsin digestion, and then stained with 
FITC-annexin V, followed by flow cytometry (18). 
 
Reverse transcription/Real-time PCR (RT/qPCR) 
Tg and wild type islets were isolated and cultured in the absence or presence 
of IFN-γ (0.5 μg/ml)  plus IL-1β (0.5 ng/ml), or TNF-α (100 ng/ml) plus 
IL-1β (0.5 ng/ml). The islets were then harvested, and their total RNA was 
extracted with Trizol (Invitrogen, Carlsbad CA). RNA was 
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reverse-transcribed into cDNA by M-MLV Reverse Transcriptase Kit. 
QIAGEN Quanti-Test SYBR Green PCR Kits were employed for all 
real-time PCR amplification of cDNA templates. The PCR amplification 
program was: 95oC, 15 min, 1 cycle; 95oC, 10 sec, 56oC, 15 sec, 72oC, 20 
sec, 45 cycles. The primers for LIGHT, TL1A, HVEM, LTβR and DR3 
mRNA quantification are listed in Table I-A. The primers for DNA 
microarray data verification on IFN-γ/IL-1β−  and TNF-α/IL-1β-treated 
islets are listed in Table I-B and Table I-C, respectively. In addition to 
melting curve analysis, the PCR products were also resolved by agarose gel 
electrophoresis to ascertain that the expected band-size was obtained.  
 
Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labelling 
(TUNEL) assay 
Apoptosis of islet cells treated with recombinant mouse LIGHT (R&D 
Systems, Minneapolis, MN) and TL1A (R&D Systems) were analyzed by a 
fluorescent TUNEL assay, using the In Situ Cell Death Detection Kit (Roche 
Diagnostics GmbH, Mannheim, Germany) followed by flow cytometry, 
according to manufacturer’s instructions.  
 
Insulin release assay 
The assay was conducted as reported elsewhere (17). 
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DNA microarray analysis 
Three independent batches of islet isolation were carried out. For each batch, 
islets were obtained from 4 Tg and 4 WT mice, and pooled respectively. The 
pooled islets (Tg or WT) were then divided into 4 groups: 2 were cultured in 
the presence of IFN-γ (0.5 μg/ml) plus IL-1β (0.5 ng/ml) with 1 harvested at 
24 h and 1 harvested at 48 h; 2 were cultured in the presence of TNF-α (100 
ng/ml) plus IL-1β (0.5 ng/ml) with 1 harvested at 24 h and 1 harvested at 48 
h. Τotal RNA was extracted from Tg and WT islets with QIAGEN RNeasy 
Micro Kits. After reverse transcription, cDNA served as a template for 
PCR-based cRNA amplification. cRNA was then reverse-transcribed to 
produce second-generation cDNA, which was employed to generate 
biotin-labelled cRNA probes. The probes were hybridized on the GeneChip 
Mouse Genome 430 2.0 Array (Affymetrix, Santa Clara, CA), which 
contains 39,000 transcripts. DNA microarray analysis was performed at the 
McGill University Genome Quebec Innovation Centre. Each treatment 
employed 3 chips using RNA from 3 different batches of islet isolation. For 
each treatment, genes with a mean signal strength difference above 2-fold 
between Tg and WT islets were selected for reversePCR confirmation. 
Details of the experimental protocols and data analysis procedure can be 
found in http://genomequebec.mcgill.ca/centre.php and 
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http://www.affymetrix.com/corporate/outreach/lesson_plan/downloads/manu
facturing_teachernotes.pdf.  
 
Islet transplantation 
Diabetes in mice were chemically induced by injecting C57BL/6 male mice 
(6-10 weeks old) with streptozocin (STZ, 90 mg/kg) 3 times q.2.d. Three 
weeks after STZ injection, blood glucose was monitored every day with an 
Ascensia Contour glucose meter until it was above 20 mM for 2 consecutive 
days. Two hundred islets from Tg or WT mice were injected i.p. in diabetic 
recipients. Blood glucose was measured once every day for the first 7 days 
after transplantation and then once every 3 days.  
 
Plasmid construction and transfection 
Full-length (2113 bp) mouse Adcyap1 cDNA (clone 6829765; Open 
Biosystems, Huntsville, AL) was cloned into a mammalian cell expression 
vector pCEP4 (Invitrogen, Carlsbad, CA) at Kpn1 and Not1 sites 
downstream of the CMV promoter. The resulting plasmid is named 
pCEP4-Adcyap1. The plasmid was transfected into NIT-1 insulinoma cells 
using X-tremeGENE Transfection Reagent (Roche Diagnostics, 
Mannheim,Germany) according to manufacturer’s instruction (2 μg/ml 
plasmid for 0.2 x 105 NIT-1 cells/0.2 ml/well in 48-well plates). The mRNA 
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overexprssion of Adcyap1 in the transfected cells was confirmed by 
RT/qPCR after 48 h. The cells were treated with or without IFN-γ (3 μg/ml) 
plus IL-1β (3 ng/ml) 24 h after the transfection. Cell apoptosis was assessed 
by annexin V staining after additional 48 h with flow cytometry.  
 
Bank1 siRNA transfection  
Two pairs of mouse Bank1 siRNA were synthesized (Integrated DNA 
Technologies, Coralville, IA). The sequences of the first pair were 
rArGrArArArCrArArCrArCrCrUrUrArCr and 
rUrUrGrArGrCrUrArUrGrUrArArGrGrUr, and the second pair, 
rGrGrArCrUrUrArCrUrArArArUrGrUrCr and 
rUrGrArGrArGrArArArGrArCrArUrUrUr. Scrambled Negative Control 
Duplex siRNA was used as controls. The sequences of the controls were 
rCrUrUrCrCrUrCrUrCrUrUrUrCrUrCrUrCrCrCrUrUrGrUGA, and 
rUrCrArCrArArGrGrGrArGrArGrArArArGrArGrArGrGrArArGrGrA. The 
paired siRNA was first heated to 94oC for 2 min and then cooled to the room 
temperature for annealing. The 2 pairs of annealed Bank1 siRNA were 
mixed at a 1:1 ratio and transfected into NIT-1 cells by X-tremeGENE 
transfection reagent (Roche Diagnostics GmbH, Mannheim,Germany) at the 
final concentration of 0.1μM siRNA for 0.2 x 105 NIT-1 cells/0.2 ml/well in 
48-well plates. Bank1 mRNA knockdown was confirmed by RT/qPCR 48 h 
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after the transfection. The primers used for this purpose were 
TTATAAACAGACCACCGGCTCCCA and 
TCACCATCAGATTGTCTTCGGGCT. The cells were treated with or 
without IFN-γ (3 μg/ml) plus IL-1β (3 ng/ml) 24 h after the transfection. 
Cell apoptosis was assessed by annexin V staining after additional 48 h with 
flow cytometry. 
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RESULTS 
 
DcR3 Tg islets secrete DcR3 
To continuously supply biologically active DcR3 to islets, DcR3 Tg mice 
were generated in both the C3H x C57BL/6 and C57BL/6 backgrounds, 
using the human β-actin promoter, as described in our previous publication 
(19). Two Tg mouse lines were generated. Line 754, originally in the C3H x 
C57BL/6 background, was backcrossed to the C57BL/6 background for 8 
generations. Line 17139 was generated in the C57BL/6 background. Both 
lines have a similar phenotype. They are fertile and present no gross 
anomalies before 5 months of age (19). After 5 months, these mice develop a 
systemic lupus erythematosus-like syndrome (19). For this study, only 2- to 
5 month-old mice were used. We demonstrated that DcR3 Tg islet cells from 
both lines were able to secrete DcR3 into culture supernatants at 8-15 
ng/ml/200 islets within 24 h, as expected (Fig. 1). The remaining results in 
this study were from line 754 islets, but line 17139 islets behaved similarly. 
 
DcR3 Tg islets are resistant to apoptosis and preserve better function in 
vitro 
DcR3 could block multiple apoptosis pathways, as reviewed in the 
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Introduction. We have demonstrated previously that recombinant DcR3 
could reduce FasL plus IFN-γ-induced islet cell apoptosis. Here, we showed 
that after 4 days of culture, Tg islet cells showed decreased apoptosis in 
plain medium (control), in medium containing IFN-γ/IL-1β, and in medium 
containing TNF-α/IL-1β, compared to WT islet cells (Fig. 2A). Such an 
effect was attributed to DcR3 produced by Tg islets themselves, since no 
exogenous DcR3 was added. 
To pin-point the different degrees of islet apoptosis to β−cells, we evaluated 
the function of Tg islets by insulin-release assay (Fig. 2B). The Tg and WT 
islets were cultured in the absence or presence of the above-described 
cytokines for 48 h before the insulin-release assay. IFN-γ/IL-1β- and 
TNF-α/IL-1β-treated WT islets had significantly reduced insulin-release 
capability, while Tg islets retained their insulin-secretion function. This 
suggests that the apoptosis in islet cells, as seen in Fig. 2A, was attributed to 
β-cells.  
 
DcR3 inhibits islet apoptosis by interfering with the TL1A/DR3 and 
LIGHT/HVEM-LTβR pathways 
DcR3 binds to FasL and thus blocks the FasL/Fas-mediated apoptosis 
pathway (20). We have proved previously that this pathway is critical in islet 
apoptosis, and the presence of recombinant DcR3 reduces islet apoptosis 
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triggered by FasL (17). As DcR3 could interfere with 2 additional death 
pathways (i.e., TL1A acting through DR3, and LIGHT acting through 
LTβR/HVEM), we investigated whether these two additional pathways 
functioned in islets and whether blocking them was a mechanism for DcR3’s 
protective effect on islets, 
 
We first analyzed the expression of ligands and receptors involved in these 2 
pathways. As shown in Figs. 3A and 3B (first rows), TL1A mRNA was 
detectable in islets cultured in medium (empty columns), and its expression 
was upregulated in the presence of IFN-γ/IL-1β, or TNF-α/IL-1β (black 
bars). LIGHT expression was not detectable in islets without stimulation; 
after 6-h IFN-γ/IL-1β or TNF-α/IL-1β stimulation, there was a transient and 
drastic induction of this gene expression (Figs. 3A and 3B; upper left panels, 
black bars). mRNA of the receptors, i.e., DR3, LTβR and HVEM, was all 
detectable in cultured islets, and they were moderately upregulated after the 
culture (Figs. 3A and 3B; second and third rows; empty bars; 6h versus 24h); 
the cytokines did not further induce their expression (Figs. 3A and 3B; 
second row; empty versus black bars), with the exception of HVEM, which 
was induced by IFN-γ/IL-1β, and by TNF-α/IL-1β  (Figs. 3A and 3B; third 
row; empty versus black bars). As a matter of fact, IFN-γ/IL-1β actually 
moderately suppressed the spontaneous DR3 upregulation, and 
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TNF-α/IL-1β modelrately hindered the spontaneous DR3 and LTβR 
upregulation after culture (Figs. 3A and 3B, second row; empty columns 
versus black columns). In summary, the components of LIGHT and TL1A 
death pathways were all present in islets, and this provided a basis for them 
to be functional there. 
  
We next investigated whether these pathways were actively involved in islet 
death, and whether DcR3 could protect islets by interfering with these 
pathways. Islets from lpr/lpr mice, whose Fas is not functional due to a 
spontaneous mutation in the gene were used, so that the involvement of 
Fas/FasL could be excluded. Freshly isolated islets had little apoptosis (Fig. 
4A). After 96 h culture in medium, 15.9% of the islet cells became apoptotic 
(Figs. 4B and D, first panel). Recombinant DcR3 could not suppress such 
spontaneous apoptosis (Fig. C. first panel). These islets were assaulted with 
recombinant mouse LIGHT (Figs. B and C) or TL1A (Fig. D). In the case of 
LIGHT, IFN-γ/IL-1β (Fig. 4B, ) and TNF-α/IL-1β (Fig. 4C) were added to 
the culture. It is to be mentioned that in this experiment, these cytokines 
were used at suboptimal concentrations, about 1/10th of that used for 
apoptosis induction (Fig. 2). As a result, after 96 h culture, islets cultured in 
the presence of cytokines (Figs. 4B and 4C, second panels) were not much 
different from that cultured in medium (Figs. 4B and D, first panels). In the 
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case of TL1A (Fig. 4D), no cytokines were added to the culture. The 
decision whether to add cytokines into the culture was made empirically, 
because our preliminary results showed that LIGHT but not TL1A needed a 
low level of cytokine priming to trigger islet apoptosis. Thus, exogenous 
LIGHT was added to the cytokine-treated islets, and exogenous TL1A was 
added to islets without cytokine treatment.  
 
The purpose of the addition of exogenous LIGHT and TL1A, in spite of the 
existence of endogenous LIGHT and TL1A in islets, to trigger apoptosis was 
2-fold, 1) If these molecules induced islet apoptosis, we will be able to 
identify these molecules as inducers of islet apoptosis, or as synergistic 
factors for apoptosis induction for islets; 2) we can use DcR3 to neutralize 
their apoptosis-inducing effect, to ascertain the specificity. 
 
Indeed, both LIGHT (Figs. 4B and 4C, third panels compared to second 
panels) and TL1A (Fig. 4D, second panel compared to first panel) 
augmented islet apoptosis after 96 h. The exogenous recombinant DcR3 
blocked such an effect (Figs. 4B-D, last panels), proving the specificity of 
the action of these 2 recombinant proteins. Therefore, for the first time, we 
demonstrated that the LIGHT/HVEM-LTβR pathway as well as the 
TL1A/DR3 pathway were involved in islet apoptosis, while DcR3 protected 
FACULTÉ  DES  ÉTUDES  SUPÉRIEURES  UNIVERSITÉ  DE  MONTRÉAL        BING HAN 163
islets by antagonizing their pro-apoptotic effect. 
 
Reduced PNF in transplanted Tg islets 
To test whether the presence of long-term local DcR3 could reduce PNF, we 
transplanted a suboptimal number (200 islets per recipient) of Tg and WT 
islets into syngeneic diabetic recipients. With such a number, only 10-38% 
of WT islet recipients could transiently achieve euglycemic status (blood 
glucose <12 mM) at a given time point in the first 16 days after 
transplantation, and all of them reversed to diabetic thereafter (Fig. 5A). On 
the other hand, 100% of Tg islets recipients became transiently euglycemic 
in the first 16 days, and 50% of them achieved long-term euglycemia (after 
23 days until the end of the experiment at day 32 post-transplantation). The 
Tg islet recipient groups also presented significantly lower mean blood 
glucose levels throughout the test period, i.e., from day 1 until day 32 
post-transplantation (Fig. 5B). This result indicated that local DcR3 presence, 
even at a very low level, rendered islet transplantation much more efficient, 
because of PNF reduction. 
 
Downstream genes involved in the DcR3 protective effect on islet apoptosis 
We conducted DNA microarray analysis to discover downstream molecules 
involved in the DcR3’s protective effect on islet apoptosis. Islets were 
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cultured in the presence of IFN-γ/IL-1β for 24h, and their mRNA was 
analyzed by DNA microarray. A total of 34 genes presented over 2-fold 
expression difference between Tg and WT islets according to the microarray. 
The difference in 5 out of these 34 genes could be confirmed by real-time 
PCR, and the list is shown in Table 2. Notably, among these 5 genes, the 
adenylate cyclase activating polypeptide 1 (Adcyap1) expression level in Tg 
islets was 779-fold higher than in WT islets, and Bank1 expression was 50 
times lower in Tg than in WT islets, after 24-h culture in the presence of the 
cytokines.  
 
For TNF-α/IL-1β-treated Tg and WT islets, expression levels of 52 genes 
differed more than 2 fold according to DNA microarray analysis, and 7 
genes presented consistent differences after real-time PCR verification. 
Among these 7 genes, in Tg islets, Ms4a4c showed 4-fold increase, and 
Ttyh1, a 7-fold decrease, with WT islets as references. 
 
DcR3 acts through Adcyap1 and Bank1 for islet protection 
We found that DcR3 Tg islets presented 779-fold higher Adcyap1 expression 
and 50-fold lower Bank1 expression compared to WT islets upon 
IFN-γ/IL-1β assualt (Table 2). We next investigated whether the modulation 
of these two genes was causative to islet survival, or just parallel events not 
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relevant to the protective effect of DcR3. Unstimulated Tg islet had about 
10-fold higher Adcyap1 expression than WT islets; upon IFN-γ/IL-1β assault, 
Tg islets maintained their high Adcyap1 levels, but WT islet drastically 
downregulated the expression (about 100 fold) (Fig. 6A). To understand 
whether the high Adcyap1 levels was protective to islets, we generated a 
mammalian cell expression construct of Acdyap1 named pCEP4-Adcyap1 
(Fig. 6B), and transfected it into NIT-1 insulinoma cells. Adcyap1 mRNA 
overexpression driven by the CMV promoter in NIT-1 cells 48 h after 
transfection was confirmed by RT-qPCR (Fig. 6C). When the empty 
vector-transfected NIT-1 cells were assaulted by IFN-γ/IL-1β, 42.5% of 
them underwent apoptosis, as expected. However, Adcyap1 overexpression 
protected NIT-1 cells from such cytokine-induced apoptosis; only 24.7% 
cells became apoptotic (Fig. 6D). A summary of data from 3 independent 
experiments is shown in Fig. 6E. This result indicates that the upregulation 
of Adcyap1 is beneficial to β-cell survival. It further implies that DcR3 
protects β-cells against IFN-γ/IL-1β through enhancing Adcyap1 expression.  
 
In WT islets, IFN-γ/IL-1β stimulation caused 10-fold augmentation of 
Bank1; the presence of DcR3 suppressed such augmentation and Bank1 
levels remained unchanged (Fig. 7A). We wondered whether this Bank1 
suppression was another DcR3’s protective mechanism for islets. To verify 
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this hypothesis, we transfected Bank1 siRNA into NIT-1 cells and Bank1 
mRNA knockdown was confirmed by RT/qPCR (Fig. 7B). We demonstrated 
that Bank1 siRNA but not control siRNA transfection resulted in reduced 
NIT-1 cell apoptosis from 36.2% to 26% upon IFN-γ/IL-1β stimulation (Fig. 
7C). A summary of data from 3 independent experiments is illustrated in Fig. 
7D. This demonstrates that repressed Bank1 expression protects β cells from 
IFN-γ/IL-1β insults, and this is another mechanism through which DcR3 
exerts its beneficial effect on β-cell survival. 
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DISCUSSION 
The novel findings of this study are as follows. 1) For the first time, the 
TL1A/DR3 pathway and the LIGHT/HVEM-LTβR pathway were found 
operative in islets and mediating islet apoptosis. 2) We demonstrated that 
DcR3 secreted by the islets in minute amounts, about 3 orders of magnitude 
less than that we administered i.p. in our previous study (17), was sufficient 
to protect islets from apoptosis. 3) Two novel downstream mediators of 
DcR3’s effect, Adcyap1 and Bank1, were discovered by DNA microarray 
and confirmed by functional studies for their protective and detrimental roles, 
respectively, in β-cells apoptosis. 
 
In our previous study, we identified the FasL/Fas pathway as a culprit in 
causing islet PNF (17), and reported that DcR3 protected islets by blocking 
that pathway. As DcR3 acts on several additional pathways, we proved in 
this study that the TL1A and LIGHT pathways were also responsible for islet 
apoptosis. This new mechanistic finding is useful for designing methods to 
reduce PNF, because now we know that all these three pathways will need to 
be blocked to achieve maximal protective effects. Our findings are also 
important in understanding the pathogenesis of diabetes, because 
IFN-γ/IL-1β and TNF-α/IL-1β are present in the milieu of type I diabetes 
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(21,22), and TNF-α/IL-1β, in type II diabetes (23,24). We have shown that 
these cytokines were able to induce LIGHT and its receptor HVEM in islets, 
to make the LIGHT apoptosis pathway operational. Although in the islets the 
receptors of LIGHT (i.e., HVEM and LTβR) expressed constitutively, albeit 
at low levels (Figs. 3A and 3B), we found that exogenous recombinant 
LIGHT alone could not induce islet apoptosis (data not shown), unless the 
islets were primed with low-dose cytokines (i.e., IFN-γ/IL-1β or 
TFN-α/IL-1β). This suggests a 2-hit modus operandi: the LIGHT-triggered 
signalling needs to interact with the cytokine-triggered signalling to achieve 
islet apoptosis. On the other hand, TL1A signalling alone seemed sufficient 
to cause islets apoptosis, in the absence of cytokine priming. Therefore, one 
hit seemed to be enough for TL1A. 
 
In our previous study (17), we administered recombinant DcR3 to mice to 
reduce PNF. The effective peak dosage was about 15 μg/ml body volume. In 
the current study, with continuous secretion of biologically active DcR3 
from islets, we estimated that DcR3 at a level of several ng per ml body 
volume (about 1000-fold lower than the exogenous recombinant DcR3 
employed before; ref. 17) was sufficient to protect the islets, as 100 Tg islets 
secreted about 8 ng DcR3 in 24 h and we transplanted 200 islets into one 
recipients. The effective DcR3 concentration at such a low level makes 
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clinical application feasible: isolated islets could be infected with 
DcR3-expressing virus vectors in islet transplantation to render themselves 
resistant to PNF. Such a measure will reduce the islet number required to 
attain recipient insulin independence. This is equivalent to an increase in the 
available donor pool, currently a limiting factor in islet transplantation. 
 
To gain mechanistic insights, we employed DNA microarrays to discover 
downstream molecules affected by the protective effect of DcR3, which 
acted on the Fas HVEM/LTβR and DR3 pathways in islets. Tg and WT islets 
were assaulted by IFN-γ/IL-1β to mimic the post-transplantation 
environment they would experience in type I diabetes recipients, and by 
TFN-α/IL-1β, in type II diabetes recipients. Five genes in the former and 7 
genes in the latter environment manifested expression differences between 
Tg and WT islets. It is surprising that these two treatments did not yield 
overlapping gene expression patterns as there was no common gene in 
Tables 2 and 3, although DcR3 acted in both cases by blocking the Fas, 
HVEM/LTβR and DR3 pathways. This reminds us of the interesting theory 
of the “butterfly effect”, which claims that a minor difference in the 
beginning of an event could lead to drastically different consequences in a 
complex world full of multiple interacting components. In our case, the 
beginning of the event, i.e., islets were treated by two different sets of 
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cytokines, was indeed different, and signalling molecules inside islet cells 
are indeed complex and highly interactive. For the time being, we do not 
clearly understand how such an initial difference travelled through the Fas, 
HVEM/LTβR and DR3 pathways and interfered by DcR3 ended up in totally 
different gene expression patterns. Nevertheless, the genes discovered could 
serve a practical purpose as putative target molecules to promote islet 
survival. 
 
Among the 12 genes identified by DNA microarray, we selected two that 
were drastically modulated for further investigation. We found that in 
normal islets, upon inflammatory cytokine stimulation, there was a 2-order 
magnitude decrease of Adcyap1 expression. On the other hand, DcR3 Tg 
islets had about a 10-fold higher basal Adcyap1 level compared to WT islets, 
and this level did not decrease upon the cytokine stimulation. So the end 
result was that there was more than 700-fold differences in Adcyap1 
expression between Tg and WT islets. The active Adcyap1 is a short secreted 
peptide (27 or 38 amino acid residues, derived from the same precursor 
peptide) belonging to the vasoactive intestinal polypeptide superfamily, and 
is also a neurotransmitter (25). It is secreted by neurons and many other 
tissues including β-cells (26). It has profound effects in various tissue and 
organs. It is involved in circadian rhythm (27,28), cerebellum development 
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(29,30), energy homeostasis and regulation of body weight (31,32), embryo 
implantation (33), inhibition of inflammation (34), promotion of regulatory 
T cell generation (35), maintenance of pulmonary vascular tone (36), to 
name a few of its functions. The following Adcyap1 functions are probably 
directly related to the findings in this study. 1) Adycap1 is anti-apoptotic for 
neurons experienced ischemia (37). 2) It is present in the nerve fibers 
innervating the islets (38), and is produced by β-cells (26). 3) Adcyap1 can 
stimulate insulin release (38) by β-cells. 4) Transgenic Adcyap1 
overexpression in islet β-cells protects β-cells from STZ-induced apoptosis 
and renders the Tg mice resistant to STZ-induced diabetes. (39). These 
anti-apoptotic and islet protective effects are in consistent with our finding 
that: 1) Adcyap1 overexpression protects β-cells from inflammatory 
cytokine-induced apoptosis, 2) Tg islets maintained high levels of Adcyap1 
expression while WT islets drastically reduced Adcyap1 expression upon 
cytokine assault, and 3) high Adcyap1 expression in Tg islets was associated 
with reduced apoptosis.  It seems that DcR3 not only directly protected 
islets by interfering with Fas, Hvem and DR3 death pathways, but also 
hijacked an additional β-cell trophic molecule Adcyap1 to achieve its 
beneficial effect on islets.  
 
Bank1 is the other molecule that showed major difference in expression 
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between Tg and WT islets. WT islets upregulated Bank1 expression 50 times 
upon cytokine stimulation, while its expression remained almost unchanged 
in Tg islets. Bank1 is an adaptor protein and a substrate of Lyn tyrosine 
kinase ( 40 ). It forms tri-molecule complex with Lyn and IP3R; its 
overexpression leads to enhanced calcium mobilization from intracellular 
stores in B cells upon B cell receptor activation. In islet β-cells, it is known 
that calcium fluxes are required for IL-1β-and glucose-induced apoptosis 
(41). Thus, a plausible additional mechanism for DcR3 to protect β-cells is 
to inhibit cytokine-induced Bank1 upregulation, the truncation of which in 
turn represses the pro-apoptotic calcium fluxes in the cells. 
 
How the interference of Fas, Hvem and DR3 signaling by DcR3 leads to the 
prevention of Adcyap1 downregulation and Bank1 upregulation in β-cells 
remains to be investigated. Obviously, the DcR3 presence also affects the 
expression of multiple genes, some of which might also be true mediators of 
DcR3’s protective effect. Further functional relevance verification of these 
identified genes is necessary. The two verified mediator, Adcyap1 and 
Bank1, and other verified genes can serve as therapeutic targets to promote 
islet survival in the future. 
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TABLES 
 
Table 1-A. Real-time PCR primers used to quantify mRNA levels of LIGHT, TL1A, 
HVEM, LTβR and DR3. 
 
Table 1-B. Real-time PCR primers to quantify mRNA levels of microarray-identified 
genes from IFN-γ plus IL-1β-treated Tg versus WT islets. 
 
Table 1-C. Real-time PCR primers to quantifying mRNA levels of microarray-identified 
genes from TNF-α plus IL-1β-treated Tg versus WT islets. 
 
 
 
Gene Symbol Forward Primer Reverse Primer Product Size
LIGHT AGACTGCATCAACGTCTTGG TTGGCTCCTGTAAGATGTGC 128 
TL1A GATCTGAGCCTTCACCACAG AATTGTCAGGTGTGCTCTCG 68 
HVEM CAGGGCAGAGGGTAGAGAAG CCAAGTGAGAAGGTCCCTGT 82 
LTβR TCTCTGCAGAAAGCTGGGTA AGACATGGGTAGGAGTGGCT 124 
DR3 TCTAGGAGTCGCGTTCCTTT AGAGATGGGCAGTCTGTGGT 131 
Gene Symbol Forward Primer Reverse Primer Product Size
Adcyap1 GCCCGCTGTCCTACTTAGTC AGGTGAACAGGAGACACTGCT 117 
Bank1 CAGACCTGCTGCATATTGCT CTTGCTTGCTATTTCTGCCA 99 
Cryab GATTGACACCGGACTCTCAG AGAGAAGTGCTTCACGTCCA 76 
Cyp7b1 TTTCCTGCAGTCAACAGGTC TCTCGGATGATGCTGGAGTA 141 
Gap43 CCAAGCTGAGGAGGAGAAAG TCAGGCATGTTCTTGGTCAG 106 
Gene Symbol Forward Primer Reverse Primer Product Size
Gngt2 AGATTTCTCAGCTGATGAGGCGCT TCACTTCCTTCTTCAGCTGCTCCA 178 
Ms4a4c AATGGGTGTAGTCAGTGTGGCTGT ACCTCGCTGGAGTTACAACAGGAA 171 
Plat TACAATGCAAGGAGGCCAAATGCC AGACATAGCACCAGGGCTTCAAGT 97 
Scand1 ACCAAGGAGCAGATCGTGGAGAT ATTCAGGGTAGGGTGTCAGTCCAA 156 
Slc28a2 GAAGGTTGCCTGGTTCCTGCAAAT TGCTATGGTAGCAAAGCCTCCAGT 178 
Tmem45b TGCTCTCTGCATCGTAGCCATCAA TGCTTGATGTCACTCCTCATCCGA 163 
Ttyh1 ACCCTTTCAACCCTCAGGAATCCA AGCAGGTTGCCATCCTAAGTGAGA 198 
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Table 2.  Genes identified by DNA microarray and verified by real-time PCR from 
IFN-γ plus IL-1β-treated Tg versus WT islets 
 
Thirty-four gene transcripts were found modulated above 2-fold in Tg islets compared 
with WT islets after IFN-γ plus IL-1β treatment, according to DNA microarray. These 
34 transcripts were verified using real-time PCR, and 5 of them were proven to be 
modulated above 2 fold at either 24 h or 48 h after the cytokine treatment in 2 
independent experiments. The mean signal ratios of Tg versus WT islets from a 
representative experiment at 24 h and 48 h are shown. 
Gene Symbol Category 
Tg/WT signal ratio  
 at 24 h 
Tg/WT signal ratio 
at 48 h 
Adcyap1 Islet survival and function 779.15 470.70 
Bank1 Cell survival 0.02 0.30 
Cryab Apoptosis, insulin secretion 2.22 2.83 
Cyp7b1 Immune modulator 0.46 0.29 
Gap43 Proliferation 1.74 3.14 
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Table 3.  Genes identified by DNA microarray and verified by real-time PCR from 
TNF-α plus IL-1β-treated Tg versus WT islets 
 
Fifty-two gene transcripts were found modulated above 2-fold in Tg islets compared 
with WT islets after IFN-γ plus IL-1β treatment, according to DNA microarray. These 
52 transcripts were verified using real-time PCR, and 7 of them were proven to be 
modulated above 2 fold at either 24 h or 48 h after the cytokine treatment in 2 
independent experiments. The mean signal ratios of Tg versus WT islets from a 
representative experiments at 24 h and 48 h are shown. 
 
 
Gene Symbol Category 
 Tg/WT signal ratio 
at 24 h 
Tg/WT signal ratio 
at 48 h 
Gngt2 Signal transducer activity 0.83 2.25 
Ms4a4c Signal transduction 4.37 4.83 
Plat Inflammation, apoptosis 0.48 1.45 
Scand1 Regulation of transcription 2.68 1.85 
Slc28a2 Sodium-dependent nucleoside transporter 0.35 0.82 
Tmem45b Unknown 0.45 1.27 
Ttyh1 Cell-cell, cell-substrate  adhesion 0.14 0.72 
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FIGURES AND LENGENDS 
 
Figure 1. DcR3 secretion by Tg islets  
 
Islets from Tg lines 754 and 17139 and from WT mice were cultured for 24 h (100 
islets/0.5 ml/well in 24-well plates). The supernatants were harvested and analyzed by 
ELISA for DcR3 concentration. Samples were in triplicate. The experiments were 
repeated at least twice, and similar results were obtained. Data from a representative 
experiment are shown. 
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Figure 2. Tg islets present reduced apoptosis and maintain their function under 
cytokines assault  
 
A. Tg and WT islets were cultured in the absence or presence of IFN-γ (0.5 μg/ml) 
plus IL-1β (0.5 ng/ml), or TNF-α (100 ng/ml) plus IL-1β  (0.5 ng/ml) for 4 days. They 
were harvested and then dispersed by trypsin-digestion. Their apoptosis were analyzed 
by annexin V staining, followed by flow cytometery. The percentage of annexin 
V-positive islet cells is indicated.  
 
B.  Tg and WT islets were cultured as described in A. After 48 h, 10 islets were 
hand-picked from each treatment, and transferred to 12-well plates. The islets were 
sequentially incubated with 2.8 mM and 16.7 mM glucose. Insulin concentrations in the 
supernatants after each treatment were analyzed by ELISA. Samples were in triplicate. 
The insulin secretion ratio was calculated as follows: 
Insulin secretion ratio = insulin concentration after 16.7 mM glucose treatment/insulin 
concentration after 2.8 mM glucose treatment. 
The experiments were repeated 3 times, and data from a representative experiment are 
shown. 
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Figure 3. Expression of TL1A and LIGHT pathway components in islets according to 
real-time PCR 
 
 
WT islets were cultured in the absence (medium) or presence of IFN-γ (0.5 μg/ml) plus 
IL-1β (0.5 ng/ml) or TNF-α (100 ng/ml) plus IL-1β  (0.5 ng/ml). They were harvested 
at 6 h, 24 h, and 48 h after culture. Their TL1A, LIGHT, DR3, LTβR and HVEM 
mRNA levels were assessed by real-time PCR after reverse transcription. 
A. Islets treated with IFN-γ  plus IL-1β 
B. Islets treated with TNF-α  plus IL-1β 
 
The experiments were repeated twice, and data from a representative experiment are 
shown. 
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Figure 4. Recombinant mouse LIGHT and TL1A induced lpr/lpr islet cell apoptosis 
 
Islets from lpr/lpr mice were cultured in the absence or presence of IFN-γ (0.05 μg/ml) 
plus IL-1β (0.05 ng/ml), or TNF-α (10 ng/ml) plus IL-1β (0.05 ng/ml), as shown. In 
some experiments, recombinant mouse LIGHT (5 μg/ml) and TL1A (100 ng/ml), and 
recombinant human DcR3 (5 μg/ml) were added, as indicated. The histogram in the 
first column is from freshly isolated islets; all other histograms were from islets 
cultured for 96 h. The islets were dispersed and stained by fluorescent TUNEL, and 
were analyzed by flow cytometry. 
 
The experiments were repeated 2-4 times, and data from a representative experiment 
are shown. 
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Figure 5. Reduced islet PNF in transplantation using DcR3 Tg islets  
 
Suboptimal number of Tg or WT islets were transplanted i.p. into syngeneic C57BL/6 
mice with STZ-induced diabetes (200 islets/mouse). Recipient blood glucose was 
monitored everyday for the first 7 days, and once every other day from days 8 to 30 
after transplantation. 
A. Percentage of mice with normoglycemia (below 12 mM) after transplantation  
B. Blood glucose concentration after transplantation 
 
The data were analyzed with Student’s t test. * and ** indicate p<0.05 and p<0.01, 
respectively. 
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Figure 6. Adcyap1 overexpression protected β-cells from cytokine-induced apoptosis 
 
A. Adcyap1 mRNA expression in Tg and WT islets upon cytokine-stimulation 
Tg and WT islets were stimulated with IFN-γ (0.5 μg/ml) plus IL-1β (0.5 ng/ml) for 24 
and 48 h, and their Adcyap1 mRNA levels were assessed by RT/qPCR. The ratios 
(mean + SD) of Acdyap1 versus β-actin signals were expressed in a log scale. 
 
B. Adcyap1 expression construct 
Full-length (2113 bp) mouse Adcyap1 cDNA was cloned into a mammalian cell 
expression vector pCEP4 at Kpn1 and Not1 sites downstream of the CMV promoter. 
The resulting plasmid is named pCEP4-Adcyap1, and was used for NIT-1 cell 
transfection.  
 
C. Adcyap1 overexpression  in pCEP4-Adcyap1-transfected NIT-1 cells 
Plasmid pCEP4-Adcyap1 was transfected into NIT-1 insulinoma cells. Adcyap1 mRNA 
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in the transfected cells was measured by RT/qPCR after 48 h. The ratios (mean + SD) 
of Bank1 versus β-actin signals are shown. 
 
D and E. Adcyap1 overexpression in NIT-1 cells reduced cytokine-induced apoptosis 
NIT-1cells were transfected with pCEP4-Adcyap1 or the empty vector pCEP4. The 
cells were treated with or without IFN-γ (3 μg/ml) plus IL-1β (3 ng/ml) 24 h after the 
transfection. Cell apoptosis was assessed by annexin V staining after additional 48 h 
with flow cytometry. A representative set of histograms are shown in panel D, and a 
summary of data from 3 independent experiments are illustrated in panel E. The 
difference between pCEP4- and pCEP4Adcyap1-transfected cells is highly significant 
(p<0.05, Student’s t test). 
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Figure 7. Inhibition of Bank1expression decreased cytokine-induced apoptosis in 
NIT-1 cells 
 
A. Bank1 mRNA expression in Tg and WT islets upon cytokine-stimulation 
Tg and WT islets were stimulated with IFN-γ (0.5 μg/ml) plus IL-1β (0.5 ng/ml) for 24 
and 48 h, and their Bank1 mRNA levels were assessed by RT/qPCR. The ratios (mean 
+ SD) of Bank1 versus β-actin signals are shown. 
 
B. Bank1 mRNA knockdown  in Bank1 siRNA-transfected NIT-1 cells 
Bank1 siRNA or control siRNA was transfected into NIT-1 insulinoma cells. Bank1 
mRNA in the transfected cells was measured by RT/qPCR after 48 h. The ratios (mean 
+ SD) of Bank1 versus β-actin signals are shown. 
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C and D. Bank1 knockdown in NIT-1 cells reduced cytokine-induced apoptosis 
NIT-1cells were transfected with Bank1 or control siRNA. The cells were treated with 
or without IFN-γ (3 μg/ml) plus IL-1β (3 ng/ml) 24 h after the transfection. Cell 
apoptosis was assessed by annexin V staining after additional 48 h with flow cytometry. 
A representative set of histograms are shown in panel C, and a summary of data from 3 
independent experiments are illustrated in panel D. The difference between Bank1- and 
control siRNA-transfected cells is highly significant (p<0.05, Student’s t test). 
 
 
 
 
 
III.Discussion 
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In our studies, we investigated the relationship between DcR3 and the 
pathogenesis of the SLE. Elevated serum DcR3 levels were frequently 
found in human SLE, and DcR3 overexpression induced a lupus-like 
syndrome in mouse. We also exploited the mechanisms of DcR3 in islet 
protection and found that LIGHT and TL1A were involved in islet 
apoptosis. Furthermore, we discovered that Adcyap1 and Bank1 were 
downstream molecules mediating DcR3’s effect. Several issues related to 
our findings are discussed below.  
 
1. DcR3 and the pathogenesis of SLE 
The defect of Fas or FasL causes lupus like syndromes in mouse models. 
However, in humans, simple mutations in Fas or FasL do not lead to 
typical SLE, and SLE patients do not have genetic abnormality of Fas/FasL. 
Moreover, apoptosis of peripheral lymphocytes in SLE patients is 
increased both in vivo and in vitro. These conflicting findings about the 
relationship between Fas-mediated apoptosis signaling pathway and SLE 
pathogenesis are puzzling. 
Here we found that DcR3, a blocker for multiple apoptosis pathways, was 
present at high levels in human SLE patients, and DcR3 overexpression 
induced a lupus-like syndrome in a mouse model. We further demonstrated 
that hematopoietic cell-restricted overexpression of DcR3 was sufficient 
FACULTÉ  DES  ÉTUDES  SUPÉRIEURES  UNIVERSITÉ  DE  MONTRÉAL       BING HAN 192
for the pathogenesis of an SLE-like disease in mice.  
Our finding reveals several possible mechanisms of SLE pathogenesis 
involving the Fas apoptosis pathway. They are discussed as follows.  
1-1 . The DcR3 overexpression in self-reactive lymphocyte interferes with 
their anergy.  
In our investigation, we found that elevated DcR3 serum levels occur in 
healthy population more frequently (>2%) than the prevalence of SLE 
(~0.05-0.1%). We do not know whether the higher expression of DcR3 in 
this “healthy population” is due to undetected underlying tumors or other 
disease conditions, but it is not due to acute inflammation (1). Also, serum 
levels of DcR3 in many malignant tumor patients (1) were similar to those 
in SLE patients. Although autoantibodies (including anti-dsDNA 
antibodies) were found in such tumor patients (2), they do not have 
increased SLE incidence. These suggest that high level serum DcR3 alone 
is not sufficient for SLE pathogenesis. However, DcR3 produced by 
lymphoid cells seems to be more relevant to SLE pathogenesis. DcR3 is 
overexpressed in a variety of lymphoma cells (3) and in PBMC of SLE 
patients (4), SLE patients have increased incidence of lymphomas (5,6). It 
is possible that only high levels of DcR3 in the micro-environment around 
lymphocytes, especially auto-reactive lymphocytes, is responsible for 
breaking self-tolerance. 
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According to this hypothesis, DcR3 can be up-regulated in various cells 
and tissues due to genetic susceptibilities and environmental factors. Under 
most conditions, such up-regulation only causes increased risk of certain 
cancers. However, when this occurs in or near auto-reactive immune cells, 
SLE is initiated.  
To take the Epstein-Barr virus (EBV) infection as an example, it has been 
related to increased incidence of both SLE and lymphoma (7,8). EBV also 
elevates DcR3 expression through a Rta-dependent pathway. It implies 
causality among EBV infection, DcR3 expression, SLE, and lymphoma. 
The EBV infection of B lymphocytes may be the initial event in the 
pathological process: it induces DcR3 overexpression in B lymphocytes. 
Elevated DcR3 will increase the risk of malignant change of EBV-infected 
B lymphocytes. When this infection occurs in auto-reactive B lymphocytes 
or near auto-reactive T cells, increased DcR3 will not only elevate the risk 
of lymphomas, but also boost these auto-reactive lymphocytes to break 
self-tolerance and trigger SLE pathogenesis.   
 
The high local DcR3 concentration in or near auto-reactive lymphocytes 
interferes with self–tolerance by blocking the Fas/FasL apoptosis pathway 
of these cells, but the elements of the Fas pathway are not compromised 
during this process. Thus, the Fas signaling pathway works normally 
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everywhere else except in the micro-environment.  
This hypothesis can explain why the apoptosis of peripheral lymphocyte 
increase in SLE patients. While a small proportion of auto-reactive 
lymphocytes are protected by an in situ high concentration of DcR3, most 
of DcR3 negative lymphocytes are still susceptible to apoptosis. Anti-
lymphocyte autoantibodies and disordered cytokines in SLE patients will 
lead to increased apoptosis of those normal lymphocytes, which are not 
essential for SLE generation. 
 
1-2 . DcR3 impairs the clearance of apoptotic cells and increases 
autoantigen presentation. 
It has been reported that clearance of apoptotic debris by phagocytes is 
impaired in SLE patients (9). Impaired removal of apoptotic cells and 
debris may lead to the exposure of autoantigens to the immune system. In 
SLE patients, apoptotic debris accumulates in germinal centers (GC) (10), 
bone marrow (11), and attached to the surfaces of follicular dendritic cells 
(FDC) (12). These exposed cell components may break self -tolerance (13). 
DcR3 can significantly suppress the expression of CD14, CD16 
(FcgammaRIII), and HLA-DR on the macrophage (14). DcR3 also inhibits 
chemotaxis and phagocytic activity of macrophages (14, 15 ). Thus, 
clearance of apoptotic cells/debris by macrophages in the presence of 
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DcR3 may be compromised. This may be one of the pathogenic 
mechanisms of DcR3-induced SLE. 
 
1-3 . DcR3 increases the memory T cell pool and enhances the secondary 
immune response to autoantigens 
T cells can be divided into naive T cells and memory T cells based on 
previous exposure to antigens. When naive T cells are exposed to antigens 
in lymphoid tissues, some of them will differentiate into effector cells and 
then undergo activation-induced cell death (AICD). Others will 
differentiate into memory T cells, and circulate throughout the body. 
Memory T cells can be further categorized into central memory T cells 
(TCM) and effector memory T cells (TEM), according to the expression of 
cell surface markers. TCM circulate in peripheral blood and migrate into 
T-cell areas of secondary lymphoid organs (16). They display a capacity 
for self-renewal (17) and IL-2 production. TEM exist mainly in local tissue 
or peripheral blood; they can react immediately after exposure to antigens 
again, and produce effector cytokines like IFN-γ and IL-4. In SLE patients, 
the ratio of naïve T cells/ memory T cells is decreased (18,19) and the 
number of activated TEM is increased as well (20).  
In our DcR3 Tg mouse model, we demonstrated that the DcR3 could block 
AICD of activated naïve T cells via inhibiting the Fas-FasL and probably 
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other apoptosis pathways, and probably by doing so, drives more activated 
cells into memory T cells, especially TEM. The increased TEM would 
more easily react to autoantigens in local tissue and cause severe 
inflammation. 
 
1-4 . DcR3 disturbs B-cell homeostasis and tolerance. 
SLE is an autoimmune disease dependent on both T- and B-cells. B cell 
hyperactivity has been identified as a central feature in SLE patients (21). 
Among B-cell populations, there is one subset called B1a cells, which 
expresses the T cell surface marker CD5. These cells are present in the 
peripheral blood and coelomic cavity, and produce low affinity IgM 
polyreactive antibodies, some of which can recognize autoantigens. 
Besides secretion of low affinity autoantibodies, B1a cells also produce 
high levels of IL-10, and enhance their own capacity for antigen 
presentation (22,23). B1a cells constitutively express FasL (24) and 
express Fas upon activation (25). 
Expanded B1a subset is observed in both human SLE and murine lupus 
models (22,26). This phenomenon was also found in our DcR3 Tg mouse 
model. Such expansion may be related to the defect of Fas-induced 
apoptosis of B cells, because this expansion is also present in human ALPS, 
an autoimmune syndrome caused by Fas gene mutation (27). In the mouse 
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lupus model, autoantibody producing B1a cells have low Fas expression 
and resistance to anti-Fas Ab induced apoptosis (28). This implies that the 
Fas/FasL-induced apoptosis is important to the homeostasis and self-
tolerance of B cells. DcR3 may inhibit B1a apoptosis and favor 
autoantibody production through blocking Fas pathway.  
 
1-5 . DcR3 favors Th2 development 
In contrast to the MRL/lpr mouse model, which inclines to Th1 responses 
(29), human SLE shows more Th2 responses (30). Th2 cytokines lead to B 
cell hyperactivity and autoantibody production in SLE (31). Our DcR3 Tg 
lupus mouse model also exhibited a Th2-prone immune response, 
including increased IL-4 secreting CD4+ T cells and enhanced Th2 type 
immunoglobulins. Such a bias is observed in human lupus as well: IgE 
production is elevated in DcR3 positive SLE patients.  
Such an effect of DcR3 might be achieved through dendritic cells (DCs). 
Hsu et. al. showed that DcR3 up-regulates CD86/B7.2 expression and 
suppresses CD54/ICAM-1 expression in human DCs (32). DcR3-treated 
DCs enhance IL-4 production of naïve CD4+ T cells.   
 
We have listed above several possible mechanisms by which DcR3 could 
trigger SLE pathogenesis. We noted that only about 50% of SLE patients 
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are serum DcR3 positive at a given time point. For this subgroup, DcR3 
could be used as a therapeutic target. Neutralizing or inactivating DcR3 
might increase elimination of auto-reactive lymphocytes and reestablish 
immune tolerance to self-antigens, and stop SLE progression. 
It remains to be investigated whether DcR3 negative patients are negative 
during the full course of SLE. If so, it will indicate that DcR3 is only 
responsible for SLE pathogenesis in a subgroup of SLE patients. This 
assumption is compatible with the fact that SLE is a polygenic disease.    
 
2. The mechanisms by which DcR3 protects pancreatic islets 
Our group previously used recombinant DcR3 to protect islet grafts from 
PNF for the first time. Recombinant DcR3 effectively blocked Fas/FasL-
mediated islets apoptosis, which was induced by multiple cytokines (33). 
Thus, we employed DcR3 transgenic mouse islets in the study of PNF 
prevention, and its underlying mechanisms. Several points are worth 
discussing.   
2-1. DcR3 Tg islet graft resisted PNF and presented long term 
normoglycemia in syngeneic diabetes mouse receiving a suboptimal dose 
of islets.  
DcR3 Tg islets showed high expression of endogenous DcR3. In the 
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syngeneic islet transplantation model, all diabetic recipient mice which 
received only a suboptimal amount of DcR3 Tg islets reached 
normoglycemia in 5 days after transplantation. Half of them achieved long 
term normoglycemia. Compared to the recipients of wild type islets, in 
which none had normoglycemia after 2 weeks post-transplant, the 
recipients of DcR3 Tg islets performed favourably. Of note, the DcR3 Tg 
islets only produce minute amounts of DcR3. Our result implies that 
enhanced local DcR3 concentration near the islets is sufficient to protect 
them. 
 
2-2. DcR3 acts through the TL1A and LIGHT pathways. 
In our earlier study, we already showed that DcR3 could protect islets 
through blocking the Fas/FasL signal. Here we identified that this 
protection also the result of interference of the LIGHT and TL1A apoptosis 
pathway linked to DcR3. We also reported expression of LIGHT, TL1A 
and their receptors in pancreas islets. Although LIGHT and TL1A are not 
strong apoptosis inducers of islet β-cell like FasL (~15% vs. 30% inducible 
apoptosis), they may work synergistically with FasL to reduce β-cell 
survival under inflammatory conditions. 
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2-3. Using DNA microarray to identify downstream molecules of DcR3 
action.  
We compared the mRNA expression patterns of DcR3 Tg and WT islets at 
different time points after cytokine treatment. Twelve genes showed 
significant difference in their expression, especially Adcyap1 (adenylate 
cyclase activating polypeptide 1) and Bank1 (B-cell scaffold protein with 
ankyrin repeats 1). Adcyap1 is also called PACAP (pituitary adenylate 
cyclase-activating polypeptide). Its expression was maintained at high 
levels in DcR3 Tg islets, while in WT islets, its expression was reduced 
drastically (2 orders of magnitude) upon cytokine stimulation. According 
to our result, Bank1 was significantly upregulated in WT but not in Tg 
islets after cytokine stimulation. We overexpressed Adcyap1 or silenced 
Bank1 expression in NIT-1 insulinoma cells. These manipulations 
ameliorated the survival of NIT-1 cells upon cytokine assaults.  
Base on the present studies, Adcyap1, a short secreted peptide, stimulates 
insulin secretion from islets (34), increases islet mass, and protect islets 
from STZ-triggered apoptosis (35). Moreover, the human Adcyap1 gene is 
located in a T2DM susceptibility locus (35). Thus, this gene is closely 
related to islet function and survival. Its mechanism of action is still 
unclear. It might affect the regulation of intracellular calcium levels in β-
cells (36).  Bank1 is an adaptor protein, and is also a regulator of 
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intracellular calcium levels (37). DcR3 may prevent β-cell calcium flux via 
Adcyap1 and Bank1 upon cytokine stimulation. The two newly found 
intermediators may become potential novel breakthrough for promoting 
islet survival. 
 
The success of islet transplantation, the most promising potential cure for 
diabetes, is limited by the low efficacy caused by PNF. Currently, more 
than one donor is needed for a successful transplant. According to our 
studies, DcR3 is a potential protector for the islets. Adding soluble DcR3 
during islet isolation and transplantation, or genetically modifying graft 
islets to overexpress DcR3, might increase islet resistance to apoptosis 
caused by inflammation during or after transplantation. This would prolong 
islet survival, and reduce required effective doses of islet. This could be 
another therapeutic advance in islet transplantation. 
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Conclusion and Future Perspectives 
The major findings from my Ph.D. program are as follows.  
a. We discovered the DcR3 is a causative factor of SLE in a mouse model, 
and is overexpressed in human SLE; 
b. Serum DcR3 levels can be used a diagnostic parameter in clinical 
practice; 
c. DcR3 can reduce islet primary nonfunction after transplantation and 
such effect is mediated by Adcyap1 and Bank1 pathway in islets.  
These findings can be translated into clinical application in SLE and islet 
transplantation patients. 
Some interesting questions remain to be addressed in guture investigations. 
a. Can antagonists of DcR3 be employed to treat SLE? 
b. Can small molecule agonists or antagonists to Adcyap1 and Bank1 be 
developed to treat diabetes and to improve islet transplantation 
efficiency? 
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